tag:blogger.com,1999:blog-87700498021064891522024-03-12T22:07:33.555-04:00Molecular FutureCheerleading commentary and raw opinion on bio-business and molecular medicine.TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.comBlogger108125tag:blogger.com,1999:blog-8770049802106489152.post-48599542243648033242015-02-19T12:58:00.001-05:002015-02-19T12:58:06.022-05:00Tim Gallagher shared an article with you from Pocket<!-- outer container --> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="top_spacer" height="10" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <!-- tile --> <table class="tile" width="80%" border="0" cellspacing="0" cellpadding="0" align="center" bgcolor="#ffffff" style="border:1px solid #cdcdcd;border-bottom:2px solid #cdcdcd;max-width:600px;min-width:300px;"> <!-- IF rainbow bar --> <!-- ENDIF rainbow bar --> <!-- IF attribution --> <tr> <td> <table class="attribution" width="100%" cellpadding="0" cellspacing="0" border="0" bgcolor="#f8f8f8" style="font-size:18px; color:#777777"> <tr> <td class="attribution_top_spacer" colspan="3" height="21" style="font-size:1px;line-height:1px;"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td> <table width="100%" cellpadding="0" cellspacing="0" border="0" bgcolor="#f8f8f8" style="font-size:18px;color:#777777;"> <tr> <!-- If no avatar do not include profile_image td and set the second div to have a colspan="2" --> <td class="profile_image" width="53" height="40" valign="middle"><img width="40" height="40" src="http://s3.amazonaws.com/pocket-profile-images/b75adba84005d725f236a3f3e27090eb5d6456f.jpg" border="0" style="border-radius: 20px; -moz-border-radius: 20px; -webkit-border-radius: 20px; -ms-border-radius:20px" /></td> <td valign="middle"> <b style="color:#555555">Tim Gallagher</b> shared<span class="with_you"> with you</span>: </td> </tr> </table> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_vertical" colspan="3" height="13" style="font-size:1px;line-height:1px;"> </td> </tr> <!-- IF comment --> <tr> <td class="side_spacer" width="25"> </td> <td class="comment" style="line-height:22px;"> Wild clinical success stats here </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_vertical" colspan="3" height="20" style="font-size:1px;line-height:1px;"> </td> </tr> <!-- ENDIF comment --> <tr> <td height="24" class="caret" colspan="3" bgcolor="white" style="background:white url(http://email-assets.getpocket.com/caretShadow.gif) left top no-repeat;"> <!-- caret / bottom edge --> </td> </tr> </table> </td> </tr> <!-- END IF attribution --> <!-- IF item --> <tr> <td> <table width="100%" cellpadding="0" cellspacing="0" border="0"> <tr> <td class="space_above_title" colspan="3" height="26"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td> <a class="title" href="http://email.getpocket.com/wf/click?upn=taBGH0n3p5fmoPVsUKbIp9gvAh8Qsl4ZJcQW-2FLruehaNFjPWjqLoIiCW7e49wtcv0-2FyCmdcl-2Biiw5CHxcsNUOEcWrC9Hg1LVLZxMRhhr-2F06J9SDvLXPPbRAeApWQSK49U-2FRTiO8bobtjxJnVggQbkmpu8haaQ5boSwcqazw5oQiy91NYOMC0xyx-2F4KpqeRRp_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtjBthWhYfKceW4caEDB4-2BB33L3GCchGfe0zVrQl-2FkSAeEy-2BZf-2FFThCjWaEc0TVyu4EhLVx33UDIe7jfCsWGtRwdY-2FjhU7LdJ-2Bb26BUDDsd-2FbGmZZc2APKedgYp2Nud9nb5jWAtlpTZpxfqbZtB9mfAJaoL0rioAWbfaUphLC9LsR41ndE7sFuHSLCa6kqLm9rcqg4wssVdzrrO7SUDKm89zy1DxMyJ3Osaqn4lfpHkBYXf6h36SaKRzyzpm9KRmuM7L2-2F5QBlmZfESDW9alQ1DRwycyggMyUig8XPs738qVavz-2F7IsSoE2m-2FpXvM18xRzc-2FBwAkMEC4DpyWDpoPW5vlr-2Bm5s6gV0h00jVZzYdwRA-3D" style="font-weight:bold;font-size:22px;color:#3abcb6;">Forget the tech bubble. It's the biotech bubble you should worry about – Quartz</a> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="domain_spacer" colspan="3" height="7" style="font-size:1px;line-height:1px;"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td class="domain"><a style="font-size:16px;color:#999999;text-decoration:none" href="http://email.getpocket.com/wf/click?upn=pHpwG2zmVapmYMONvGrvZRYK9lLU-2FzQQgTRuVaqsQBk-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtjBthWhYfKceW4caEDB4-2BB33L3GCchGfe0zVrQl-2FkSAeEy-2BZf-2FFThCjWaEc0TVyu4EhLVx33UDIe7jfCsWGtRwdY-2FjhU7LdJ-2Bb26BUDDsd-2FbGmZZc2APKedgYp2Nud9nb5jWAtlpTZpxfqbZtB9mfAJaoL0rioAWbfaUphLC9LsRUj5jDCd-2BsrDV0kAEIBl75fl2VY-2BMldxJScM5KDYV6XUJ3NtCp3nSKokrUKo5Qxogg-2Bc9vw-2F3EzcueTn31zgkQVFE-2FE-2BT0R1vH9efN9-2B-2F60T3-2BeC8v7ulJb-2FJ-2F-2FFqNCPkp-2FCmpn6KwYOQ6NrwsozH9rKEXYsOp2hcPejXxq-2BeQmolfYNdU4UaXN-2B6ZQAnpzjw-3D">qz.com</a></td> <td class="side_spacer" width="25"> </td> </tr> <!-- IF quote --> <!-- ENDIF quote --> <tr> <td class="side_spacer" width="25"> </td> <td class="space_above_buttons" colspan="3" height="36"> </td> <td class="side_spacer" width="25"> </td> </tr> </table> </td> </tr> <!-- ENDIF item --> <!-- IF buttons --> <!-- ENDIF buttons --> </table> </td> </tr> </table> <table class="original-only" width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="card_spacer" height="12" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <!-- tile --> <table class="tile prompt_card" width="80%" border="0" cellspacing="0" cellpadding="0" align="center" bgcolor="#ffffff" style="border:1px solid #cdcdcd;border-bottom:2px solid #cdcdcd;max-width:600px;"> <tr> <td class="space_below_buttons" colspan="5" height="30"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td class="prompt_wrapper" colspan="3" style="text-align:center"> <div class="prompt_copy_wrapper" style="line-height:20px;font-size:15px;color:#000000;"> <strong>Don't have time to view this now?</strong><br> Sign up for Pocket and view this page later. </div> <div class="prompt_button_wrapper" style="margin-top:23px;"> <table class="btn" width="175" align="center" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;"> <tr> <td class="t l" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_lt.gif) left top no-repeat;" bgcolor="#ececec"> </td> <td class="t m" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_mt.gif) top repeat-x;" bgcolor="#ececec"> </td> <td class="t r" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rt.gif) right top no-repeat;" bgcolor="#ececec"> </td> </tr> <tr> <td class="l" width="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_ll.gif) left bottom no-repeat;" bgcolor="#ececec"> </td> <td class="m mid" height="26" valign="middle" align="center" style="background:#ececec url(http://email-assets.getpocket.com/btn_m.gif) bottom repeat-x;line-height:normal" bgcolor="#ececec"><a style="color:#2e2e2e;font-weight:bold;font-size:19px;text-shadow:0px 1px #ffffff;text-decoration:none;" href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavZPKhiqxluAcV-2FSL7atKgn7LTr2fcf7De9shGveQUoYVaq3QFEIi1wi9ifhu88F4MVAH-2BmbHDjzvPwi8onxDFcfwGmwZKq5MIo85AgmfcVid4L7wj9UfXQFKvoPZ7xnj6AxHJnGYtkPG1LE5ZixSCrzlACyP9HteNk5lEorJVRNp7x5c5NNSEQXJnirrY5bxij2mCxCC3bBGwjFs5huSL7gUmld3Mj-2F23Z-2FAyqxzFT1uYklHIfaRvXCSyI-2BW7RzbJSD0n7gBTqDUS6B0LiP3ZMeZEqrVxYE1UE8meD6ZfNsI8onksZkUvJZB5ui95r0L3Jqo3420SpslSJGyKmUiaqkoY6LvyLnTL7WzyzHXT85OY3qnZYtJKDYcwbF6mC0VF2CH7dfIKMFQkdADBvbl28wBtSeQMTWoNhtas1T-2BqeiHIov5bSr7hrhC-2FDwNTWXNE1kPtSOV-2BRY0e1I-2FKTACY4k6PF7jGUHnubHWyoYyUw6Cy5fds8mqZHxumJLCqAW-2FGQ-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtjBthWhYfKceW4caEDB4-2BB33L3GCchGfe0zVrQl-2FkSAeEy-2BZf-2FFThCjWaEc0TVyu4EhLVx33UDIe7jfCsWGtRwdY-2FjhU7LdJ-2Bb26BUDDsd-2FbGmZZc2APKedgYp2Nud9nb5jWAtlpTZpxfqbZtB9mfAJaoL0rioAWbfaUphLC9LsRetUGghVTa-2F3pM1YDRuIpE5LlKAFE4MUUnyf4HMX6AjXWqjtSgauVmiycXsfbdO33pDTL-2BxVoUbwnPKYWd20lBmY5AvtM7E864OO-2BjXF6eDfPNX81F7m0-2F2KOsP40aZgTTL8Neg7YPyg51wRuxyiop8Q8t1m8cGAP5P10AQak3-2FiXXTI64dyljT219vsbSEjc-3D">Get Pocket</a></td> <td class="r" width="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rr.gif) right bottom no-repeat;" bgcolor="#f8d300"> </td> </tr> <tr> <td class="b l" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_lb.gif) left bottom no-repeat;" bgcolor="#ececec"> </td> <td class="b m" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_mb.gif) bottom repeat-x;" bgcolor="#ececec"> </td> <td class="b r" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rb.gif) right bottom no-repeat;" bgcolor="#ececec"> </td> </tr> </table> </div> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_below_buttons" colspan="5" height="30"> </td> </tr> </table> </td> </tr> </table> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="footer_spacer" height="30" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <table class="footer" width="80%" style="max-width:550px" border="0" cellspacing="0" cellpadding="0" align="center"> <!-- IF footer logo --> <tr> <td align="center"><a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavUDtjNBdtwYQJc3QvCDEkCrb9rN76Px6hs8-2F3pqnF5c4pg9iI5LVq3pjjGjXWyCMbXmEotdp6EMIpfEbaAPyl9AGhktKGI5eVOEidJz8SOwtVYzxPHNU3aZjbBmRUAwaUaVoDYKd71kYdrev96vL5UlMXNA0vwsXNHW4k3dskwqs_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtjBthWhYfKceW4caEDB4-2BB33L3GCchGfe0zVrQl-2FkSAeEy-2BZf-2FFThCjWaEc0TVyu4EhLVx33UDIe7jfCsWGtRwdY-2FjhU7LdJ-2Bb26BUDDsd-2FbGmZZc2APKedgYp2Nud9nb5jWAtlpTZpxfqbZtB9mfAJaoL0rioAWbfaUphLC9LsTPxzepF6EbOP0jrc2LW4IAYD-2BpLV7h5CeOG70uid0G-2BTz24DtjLS2OXIgX0mnXIttFgfDaQyezi15DrD4jGU-2F1wEQC-2BloAVqTVf0PsmynkWrtWKY6APDKZB-2Fyrc4jJzrEnfjqLo-2FqhHZ0zDwwyfh2dDJM4oDb-2BJx015Fda-2BiABSOSqj-2BzANrwkKR0aPnerFQA-3D"><img class="pocket_embossed" border="0" src="http://email-assets.getpocket.com/pocket_embossed.gif" /></a></td> </tr> <tr> <td class="spacer_around_logo" valign="top" height="24" style="font-size:2px;"> </td> </tr> <!-- ENDIF footer logo --> <tr> <td class="footer_text" valign="top" align="center" style="font-size:11px; line-height:14px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> You are receiving this email because a friend shared to your email address from Pocket.<br/> For support requests, please contact us by going to our <a href="http://email.getpocket.com/wf/click?upn=S10v-2BfWRB4OIigzZ3tVxSzVtvnsL9TD3AibX-2F20JRgU-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtjBthWhYfKceW4caEDB4-2BB33L3GCchGfe0zVrQl-2FkSAeEy-2BZf-2FFThCjWaEc0TVyu4EhLVx33UDIe7jfCsWGtRwdY-2FjhU7LdJ-2Bb26BUDDsd-2FbGmZZc2APKedgYp2Nud9nb5jWAtlpTZpxfqbZtB9mfAJaoL0rioAWbfaUphLC9LsSOhpiLevSvp9p5lcR5fN4DzHglG6wYU06YaA6s543WTM3NVMAcBOiSl-2BVs4r1utXo3qFcXQFXlLkcAvrJSa-2BMdU67-2FP1DqhiRARm7-2BGBnPLy5U1Uu597kFM1WYUlplGJEHDGk5I6d7DVcj0Uo-2FhzBSYvbwvFrPk0Ylm9FFf8Wkp4NsBc9nDYtb7fENMbyv2KQ-3D" style="color:#666666; text-decoration:underline;">support page</a>. </td> </tr> <tr class="original-only"> <td valign="top" height="22" style="font-size:2px;"> </td> </tr> <tr class="original-only"> <td valign="top" align="center"> <table width="275" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top" align="right"> <a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavVvGMXLmRUQyPiGcf9i1vP-2BNbnTDS4YteJHmstp2XC0tyoS9FFtF-2FJFsA-2BTewSIn5TLy7dru5f7PkYBO14UskpHU7PWd8qiSlGCuEgIZqxWTpKlW5WbehjdDG1A0S8W99wrmJVoyl2mzVyUQP2RyuFK-2BwZGLc9EbTSu1lFKO-2BuqveIl65tAxQuaQLwU3kAvTbw-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtjBthWhYfKceW4caEDB4-2BB33L3GCchGfe0zVrQl-2FkSAeEy-2BZf-2FFThCjWaEc0TVyu4EhLVx33UDIe7jfCsWGtRwdY-2FjhU7LdJ-2Bb26BUDDsd-2FbGmZZc2APKedgYp2Nud9nb5jWAtlpTZpxfqbZtB9mfAJaoL0rioAWbfaUphLC9LsSoFXPEwGefOU1VGDJqSc9USlp1rjcPfPYdHIKItjRLLUOiGwRyfZ3G2Nb8Tlpa8B-2F8z33qywBn6-2BddS2sRJK8kZ4BuA6OG3kNxx5t-2FJgi9cJnkvpQyBk72xXddPqeRHRFfaOuaU85-2FbeGLqjp8xyUY7jzaujOoqvFwystGyrkrxPo93VHWkOQuKZP-2FHk1zZ28-3D" style="font-size:11px;font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;font-weight:bold;text-decoration:underline;"> Notification Settings </a> </td> <td valign="middle" align="center"> <img alt="" width="13" src="http://email-assets.getpocket.com/sep01-original.gif" /> </td> <td valign="top" align="left"> <a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavbym7-2ByxEzk5R-2FyNUsaZglMddz-2BpXt-2By6jyn3dtrmRxWKVonHrdXar4iqDYX70FEuy4tkqJDIq7aJkC9sTBnl11BeRkE6VgkcuZ5loB4VV5StnZpHe1n5J54L8Um3EHpwf004msleTgWdwcWOn-2Bp47zoOhPcNP0IMJof-2FKFesfAAdEEb5NdGHq1g24EmjrVSIw-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtjBthWhYfKceW4caEDB4-2BB33L3GCchGfe0zVrQl-2FkSAeEy-2BZf-2FFThCjWaEc0TVyu4EhLVx33UDIe7jfCsWGtRwdY-2FjhU7LdJ-2Bb26BUDDsd-2FbGmZZc2APKedgYp2Nud9nb5jWAtlpTZpxfqbZtB9mfAJaoL0rioAWbfaUphLC9LsRkq5ijjIirxvTC4VI6S59u1cgjir91YQp6KzZnhO9iaA2Crjd3pXIJns77Ic-2BN5Nikr9HlT1DP-2Brk5F-2FJga4-2B59m9D1LDXSIa4GrAQE5KESOpPGRMI28vI149toUJ5e28zVSluurBuJtaUw8elLYfyecxRRcf0jba20LtgqSl9Wn5kfLm1c-2FlukhImODdTug0-3D" style="font-size:11px;font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;font-weight:bold;text-decoration:underline;"> Privacy Policy </a> </td> </tr> </table> </td> </tr> <tr> <td valign="top" height="32" style="font-size:2px;"> </td> </tr> <tr> <td valign="top" align="center"> <font style="font-size:10px; line-height:12px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> Read It Later, Inc., 731 Market Street Suite 410, San Francisco, CA 94108, USA </font> </td> </tr> <tr> <td valign="top" height="10" style="font-size:2px;"> </td> </tr> <tr> <td valign="top" align="center"> <font style="font-size:10px; line-height:12px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> © 2013 Read It Later, Inc. All Rights Reserved. </font> </td> </tr> <tr> <td valign="top" height="30" style="font-size:2px;"> </td> </tr> </table> </td> </tr> </table> <img src="http://email.getpocket.com/wf/open?upn=5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtjBthWhYfKceW4caEDB4-2BB33L3GCchGfe0zVrQl-2FkSAeEy-2BZf-2FFThCjWaEc0TVyu4EhLVx33UDIe7jfCsWGtRwdY-2FjhU7LdJ-2Bb26BUDDsd-2FbGmZZc2APKedgYp2Nud9nb5jWAtlpTZpxfqbZtB9mfAJaoL0rioAWbfaUphLC9LsSlb74svYc7qsZMKkQIFfC63LZIs-2FSPOKpeuLMb-2BGua192QsNL3oOLPdStODwlR3tmIPKA51oDk4jGjV6-2FpouTf2aTKEPQ-2FwMo-2FbfgNNt6CUJfDdjqGVNZn50jwTkMbHKaEs1NmH20GT8Kc-2BC-2FIFq744qNO-2Feo1Gug44VOaUgmogmKw7E485QjyeZiP2u8cYdg-3D" alt="" width="1" height="1" border="0" style="height:1px !important;width:1px !important;border-width:0 !important;margin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;margin-left:0 !important;padding-top:0 !important;padding-bottom:0 !important;padding-right:0 !important;padding-left:0 !important;"/> TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-73202269177329051252014-11-30T13:43:00.001-05:002014-11-30T13:43:08.534-05:00Tim Gallagher shared an article with you from Pocket<!-- outer container --> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="top_spacer" height="10" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <!-- tile --> <table class="tile" width="80%" border="0" cellspacing="0" cellpadding="0" align="center" bgcolor="#ffffff" style="border:1px solid #cdcdcd;border-bottom:2px solid #cdcdcd;max-width:600px;min-width:300px;"> <!-- IF rainbow bar --> <!-- ENDIF rainbow bar --> <!-- IF attribution --> <tr> <td> <table class="attribution" width="100%" cellpadding="0" cellspacing="0" border="0" bgcolor="#f8f8f8" style="font-size:18px; color:#777777"> <tr> <td class="attribution_top_spacer" colspan="3" height="21" style="font-size:1px;line-height:1px;"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td> <table width="100%" cellpadding="0" cellspacing="0" border="0" bgcolor="#f8f8f8" style="font-size:18px;color:#777777;"> <tr> <!-- If no avatar do not include profile_image td and set the second div to have a colspan="2" --> <td class="profile_image" width="53" height="40" valign="middle"><img width="40" height="40" src="http://s3.amazonaws.com/pocket-profile-images/b75adba84005d725f236a3f3e27090eb5d6456f.jpg" border="0" style="border-radius: 20px; -moz-border-radius: 20px; -webkit-border-radius: 20px; -ms-border-radius:20px" /></td> <td valign="middle"> <b style="color:#555555">Tim Gallagher</b> shared<span class="with_you"> with you</span>: </td> </tr> </table> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_vertical" colspan="3" height="13" style="font-size:1px;line-height:1px;"> </td> </tr> <!-- IF comment --> <tr> <td class="side_spacer" width="25"> </td> <td class="comment" style="line-height:22px;"> Eye-opening </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_vertical" colspan="3" height="20" style="font-size:1px;line-height:1px;"> </td> </tr> <!-- ENDIF comment --> <tr> <td height="24" class="caret" colspan="3" bgcolor="white" style="background:white url(http://email-assets.getpocket.com/caretShadow.gif) left top no-repeat;"> <!-- caret / bottom edge --> </td> </tr> </table> </td> </tr> <!-- END IF attribution --> <!-- IF item --> <tr> <td> <table width="100%" cellpadding="0" cellspacing="0" border="0"> <tr> <td class="space_above_title" colspan="3" height="26"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td> <a class="title" href="http://email.getpocket.com/wf/click?upn=taBGH0n3p5fmoPVsUKbIp-2FnMM0nkDd-2By5Wg5H5wm7j2NEmNsuMtuWDYvJoBlPxZ2wGAooYRFv9jDGr0xhwNkOifFxC-2FLZTa1HxNfFA-2B8UMcdxJhg0zwz5NsGg0EzMHJCDK1MbFHFp1va5mOkm5ytxVhX15fTwKM4xCqVtiuqG7xSXSIwSFKKvQl6z7ZMSwZo_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtapsSVpQb93v8mMPwYSvBuRK-2FQsg9byTftePt8TZdl-2Bta1e6IgTmXVBh4YOnYqkQHzoPo0PfzzT7V5VhtP2jDuodiRLJVAxGluYPl1-2FFWV-2FEPt3Ig764u4jBoRzbOyugRd2XPXAgJvLjunqdYS0Fa36bCr9Ae4UcJz3ZJHtTlAfQ0YiqPUhUHbrNkM-2FYBSMIDK-2FZ5sc1cdcn27BtoOoKemrPT8K3mvcugFx00zfPrknhl8C6s-2BesBO2olCrhKvhBeRzuDHC-2FmpcEloE1M4tvU68IzvwPNF3BRINJqkCPNOd55iVbavYxYefvzkonQ0HUDtiR-2Fxb9Gf1jrn3Km709Vvy-2FJo8xhszSZzaPF0uSPCw4-3D" style="font-weight:bold;font-size:22px;color:#3abcb6;">The Case Against Early Cancer Detection</a> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="domain_spacer" colspan="3" height="7" style="font-size:1px;line-height:1px;"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td class="domain"><a style="font-size:16px;color:#999999;text-decoration:none" href="http://email.getpocket.com/wf/click?upn=ywCYSP430phO32YKi5fN-2F2ADvmJ0dNBLex64EWMJ0-2FSyHR22FngkmIgr97xaumHH_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtapsSVpQb93v8mMPwYSvBuRK-2FQsg9byTftePt8TZdl-2Bta1e6IgTmXVBh4YOnYqkQHzoPo0PfzzT7V5VhtP2jDuodiRLJVAxGluYPl1-2FFWV-2FEPt3Ig764u4jBoRzbOyugRd2XPXAgJvLjunqdYS0Fa36bCr9Ae4UcJz3ZJHtTlAfQyq-2BiO0Elnerfu7BP7mZSd5pfB6sXTaa7Z4L-2B02kvNY-2BKOz8x6RANbU32a6i5FQSIaO21lf-2BJ2ZYzfX2oqGfDZtj4g029DTASLarN7IK5WwO41ROKMJVLMuqq8aZiR7Rc8DLgDsV4ZuzXwqzLW6PI-2FXCejbU-2FmAlI1sD97ZjYP7cc5-2BdgoSjeitb35N7-2BSIH4-3D">fivethirtyeight.com</a></td> <td class="side_spacer" width="25"> </td> </tr> <!-- IF quote --> <!-- ENDIF quote --> <tr> <td class="side_spacer" width="25"> </td> <td class="space_above_buttons" colspan="3" height="36"> </td> <td class="side_spacer" width="25"> </td> </tr> </table> </td> </tr> <!-- ENDIF item --> <!-- IF buttons --> <!-- ENDIF buttons --> </table> </td> </tr> </table> <table class="original-only" width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="card_spacer" height="12" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <!-- tile --> <table class="tile prompt_card" width="80%" border="0" cellspacing="0" cellpadding="0" align="center" bgcolor="#ffffff" style="border:1px solid #cdcdcd;border-bottom:2px solid #cdcdcd;max-width:600px;"> <tr> <td class="space_below_buttons" colspan="5" height="30"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td class="prompt_wrapper" colspan="3" style="text-align:center"> <div class="prompt_copy_wrapper" style="line-height:20px;font-size:15px;color:#000000;"> <strong>Don't have time to view this now?</strong><br> Sign up for Pocket and view this page later. </div> <div class="prompt_button_wrapper" style="margin-top:23px;"> <table class="btn" width="175" align="center" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;"> <tr> <td class="t l" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_lt.gif) left top no-repeat;" bgcolor="#ececec"> </td> <td class="t m" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_mt.gif) top repeat-x;" bgcolor="#ececec"> </td> <td class="t r" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rt.gif) right top no-repeat;" bgcolor="#ececec"> </td> </tr> <tr> <td class="l" width="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_ll.gif) left bottom no-repeat;" bgcolor="#ececec"> </td> <td class="m mid" height="26" valign="middle" align="center" style="background:#ececec url(http://email-assets.getpocket.com/btn_m.gif) bottom repeat-x;line-height:normal" bgcolor="#ececec"><a style="color:#2e2e2e;font-weight:bold;font-size:19px;text-shadow:0px 1px #ffffff;text-decoration:none;" href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavZPKhiqxluAcV-2FSL7atKgn7E-2FwRnMYEcSbW-2BklyV62wKXOB-2FRw3c2-2FMpxhyfg3DoEQ0tPSIdqmK68o-2FUViEcTI-2BU16viqAeKH6TgIQ1WgXWNPIUtwOZL1rMgKahjXkusllgFfaL6OoFV6lwu-2BQ1sJPKf0hT5b-2BSHsYY-2FH19jCUPVw-2F3H6FhoiVAI3gitaUBakl3oRIU3-2Fjtc0ctQlf5Ayy-2FZ4za6zDj8jiVaUAY2gI56tFRr-2B-2BqTKsZYV3qdXidm39eWmLKlQNNj2gCLur8cx1mw-2FUYIk9LQ8Tnj8vRVKSYz7qCqDbPcH8hod4JWAFSwsyw6wW-2FHvbG-2BQVbBdIfQyIKmC6hM-2FznETBvzipLLg2-2BdJ85D2wd8VM2-2B5vmIMcxnQoxA3iQw56mkbwAwDFyWEYMQH7fpJ2aYWtKgMbdPzg9rYP9DdLRPMxDkFxaWIPb9TvbTaxNy8-2FKqWE65JDW8zBPLNi1-2BFdtaWUli5Nx7fLuFZUtrVVvw0leoX5F3o2BmVQ-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtapsSVpQb93v8mMPwYSvBuRK-2FQsg9byTftePt8TZdl-2Bta1e6IgTmXVBh4YOnYqkQHzoPo0PfzzT7V5VhtP2jDuodiRLJVAxGluYPl1-2FFWV-2FEPt3Ig764u4jBoRzbOyugRd2XPXAgJvLjunqdYS0Fa36bCr9Ae4UcJz3ZJHtTlAfQkMWEabzPeTc6SfGjhHOe8OcJDD9SUmXcfFNc2iFyI9LQAc-2Fys-2B-2F976noBDOX4sfKNU0IovuBa-2FIxzLsg6PHNwNt6mUN44CIkPHt70gbEqGL1jrOzaRfek9ONbSJN98yVyK22TMYk-2Fgph5AEAj7z3ThE6O6Hmh5BS-2Fv-2FE3-2FUgQo78d87UqPFqDobquuEytrOs-3D">Get Pocket</a></td> <td class="r" width="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rr.gif) right bottom no-repeat;" bgcolor="#f8d300"> </td> </tr> <tr> <td class="b l" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_lb.gif) left bottom no-repeat;" bgcolor="#ececec"> </td> <td class="b m" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_mb.gif) bottom repeat-x;" bgcolor="#ececec"> </td> <td class="b r" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rb.gif) right bottom no-repeat;" bgcolor="#ececec"> </td> </tr> </table> </div> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_below_buttons" colspan="5" height="30"> </td> </tr> </table> </td> </tr> </table> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="footer_spacer" height="30" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <table class="footer" width="80%" style="max-width:550px" border="0" cellspacing="0" cellpadding="0" align="center"> <!-- IF footer logo --> <tr> <td align="center"><a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavUDtjNBdtwYQJc3QvCDEkCrb9rN76Px6hs8-2F3pqnF5c4pg9iI5LVq3pjjGjXWyCMbXmEotdp6EMIpfEbaAPyl9AGhktKGI5eVOEidJz8SOwtVYzxPHNU3aZjbBmRUAwaUaVoDYKd71kYdrev96vL5UlMXNA0vwsXNHW4k3dskwqs_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtapsSVpQb93v8mMPwYSvBuRK-2FQsg9byTftePt8TZdl-2Bta1e6IgTmXVBh4YOnYqkQHzoPo0PfzzT7V5VhtP2jDuodiRLJVAxGluYPl1-2FFWV-2FEPt3Ig764u4jBoRzbOyugRd2XPXAgJvLjunqdYS0Fa36bCr9Ae4UcJz3ZJHtTlAfT3ZfduR0ujPuJgsRDsaeoz49VQ9h9MEfd9fZ65W-2BbRXcgjGNE6oA47tKkMo1UQwM0gUbdzBrMqOoaXVfdMTwVZQtHEJDthmQmfJuIywJvT-2BoZkJKG0Rdd622IAy012JGulilpK2Y8yi8JAyPH1cfxd1RuALagCNkZnlbKirOkif0iLD-2B3S6bMl58BXyCEqle4-3D"><img class="pocket_embossed" border="0" src="http://email-assets.getpocket.com/pocket_embossed.gif" /></a></td> </tr> <tr> <td class="spacer_around_logo" valign="top" height="24" style="font-size:2px;"> </td> </tr> <!-- ENDIF footer logo --> <tr> <td class="footer_text" valign="top" align="center" style="font-size:11px; line-height:14px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> You are receiving this email because a friend shared to your email address from Pocket.<br/> For support requests, please contact us by going to our <a href="http://email.getpocket.com/wf/click?upn=S10v-2BfWRB4OIigzZ3tVxSzVtvnsL9TD3AibX-2F20JRgU-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtapsSVpQb93v8mMPwYSvBuRK-2FQsg9byTftePt8TZdl-2Bta1e6IgTmXVBh4YOnYqkQHzoPo0PfzzT7V5VhtP2jDuodiRLJVAxGluYPl1-2FFWV-2FEPt3Ig764u4jBoRzbOyugRd2XPXAgJvLjunqdYS0Fa36bCr9Ae4UcJz3ZJHtTlAfQc8wZ0OW99m0AXtHVg76OXGJlpM4Ct84ImOX-2FCX-2BcNcru9R-2FMSRPL2GFoypCbVAKNVy-2BvjUcnWNLbvJQ0cN7IE76rb40b4kRoH2RJagECp1Hw4p5IA0P-2BNRPHwowvDspj5Ps7kR3yLf6GSvCpnOszJmvufCqniPEwrzSAg7k5al0qsJfPsIs9sLMVZRo3lLfk-3D" style="color:#666666; text-decoration:underline;">support page</a>. </td> </tr> <tr class="original-only"> <td valign="top" height="22" style="font-size:2px;"> </td> </tr> <tr class="original-only"> <td valign="top" align="center"> <table width="275" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top" align="right"> <a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavVvGMXLmRUQyPiGcf9i1vP-2BNbnTDS4YteJHmstp2XC0tyoS9FFtF-2FJFsA-2BTewSIn5TLy7dru5f7PkYBO14UskpHU7PWd8qiSlGCuEgIZqxWTpKlW5WbehjdDG1A0S8W99wrmJVoyl2mzVyUQP2RyuFK-2BwZGLc9EbTSu1lFKO-2BuqveIl65tAxQuaQLwU3kAvTbw-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtapsSVpQb93v8mMPwYSvBuRK-2FQsg9byTftePt8TZdl-2Bta1e6IgTmXVBh4YOnYqkQHzoPo0PfzzT7V5VhtP2jDuodiRLJVAxGluYPl1-2FFWV-2FEPt3Ig764u4jBoRzbOyugRd2XPXAgJvLjunqdYS0Fa36bCr9Ae4UcJz3ZJHtTlAfQXM-2FywwvoujLbBlRc-2FvTzjQCyis4nAGKPF5dskDLyFHeKBegOLCSEVcoUBA4oBUPx-2FVs5DyxRhCrxRPzd7cOMC2zT4vGCMaGOOykVmTvxX4uUSnDhewqITZPkid4QS2O2fIaSQJaxS5HKpwvtv5PyBeVAG3MG9qcwARD4M9oteqIuGBhH4dNLGwOpyyHcJpqQ-3D" style="font-size:11px;font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;font-weight:bold;text-decoration:underline;"> Notification Settings </a> </td> <td valign="middle" align="center"> <img alt="" width="13" src="http://email-assets.getpocket.com/sep01-original.gif" /> </td> <td valign="top" align="left"> <a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavbym7-2ByxEzk5R-2FyNUsaZglMddz-2BpXt-2By6jyn3dtrmRxWKVonHrdXar4iqDYX70FEuy4tkqJDIq7aJkC9sTBnl11BeRkE6VgkcuZ5loB4VV5StnZpHe1n5J54L8Um3EHpwf004msleTgWdwcWOn-2Bp47zoOhPcNP0IMJof-2FKFesfAAdEEb5NdGHq1g24EmjrVSIw-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtapsSVpQb93v8mMPwYSvBuRK-2FQsg9byTftePt8TZdl-2Bta1e6IgTmXVBh4YOnYqkQHzoPo0PfzzT7V5VhtP2jDuodiRLJVAxGluYPl1-2FFWV-2FEPt3Ig764u4jBoRzbOyugRd2XPXAgJvLjunqdYS0Fa36bCr9Ae4UcJz3ZJHtTlAfRPt7gOWknBWOSRsnBCXLsDpIgQvlSMT3uC-2FtmD4LgygtnC3vuUIkQGL0t82qFOVcgTrjNhjjAO8n3mgT7P6fshma0n4L5MlvdYv0ji156VktJ4fQBkkTMaTVN7iiJqcxPWeWntsVergFFa3b3Zs-2FTv17mQcwVB5epF2OWlstelxRUKFYRuqseM2EKx-2FTXT6fE-3D" style="font-size:11px;font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;font-weight:bold;text-decoration:underline;"> Privacy Policy </a> </td> </tr> </table> </td> </tr> <tr> <td valign="top" height="32" style="font-size:2px;"> </td> </tr> <tr> <td valign="top" align="center"> <font style="font-size:10px; line-height:12px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> Read It Later, Inc., 731 Market Street Suite 410, San Francisco, CA 94108, USA </font> </td> </tr> <tr> <td valign="top" height="10" style="font-size:2px;"> </td> </tr> <tr> <td valign="top" align="center"> <font style="font-size:10px; line-height:12px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> © 2013 Read It Later, Inc. All Rights Reserved. </font> </td> </tr> <tr> <td valign="top" height="30" style="font-size:2px;"> </td> </tr> </table> </td> </tr> </table> <img src="http://email.getpocket.com/wf/open?upn=5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtapsSVpQb93v8mMPwYSvBuRK-2FQsg9byTftePt8TZdl-2Bta1e6IgTmXVBh4YOnYqkQHzoPo0PfzzT7V5VhtP2jDuodiRLJVAxGluYPl1-2FFWV-2FEPt3Ig764u4jBoRzbOyugRd2XPXAgJvLjunqdYS0Fa36bCr9Ae4UcJz3ZJHtTlAfRDptZe2wo4K2KsgfYd4HV3QSzPdrPn3pZv2IaKFftxwu2VFbeZ5M5dKVPnMSoTdy73WjOl5Ugn1UHLLhz0rSZsABnt-2Bc04XOG26TRTiXhO75jZIIMLNsKPLA1Fw9GODbqI4X8J4Vgr1v8R-2Fo-2BQ-2BpXzcP9a-2F2aZ9gqCiPnuxfR0TU1iYm8LnmeiowF8UWU3JX0-3D" alt="" width="1" height="1" border="0" style="height:1px !important;width:1px !important;border-width:0 !important;margin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;margin-left:0 !important;padding-top:0 !important;padding-bottom:0 !important;padding-right:0 !important;padding-left:0 !important;"/> TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-91467308951008218502014-11-06T10:18:00.001-05:002014-11-06T10:18:10.551-05:00Tim Gallagher shared an article with you from Pocket<!-- outer container --> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="top_spacer" height="10" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <!-- tile --> <table class="tile" width="80%" border="0" cellspacing="0" cellpadding="0" align="center" bgcolor="#ffffff" style="border:1px solid #cdcdcd;border-bottom:2px solid #cdcdcd;max-width:600px;min-width:300px;"> <!-- IF rainbow bar --> <!-- ENDIF rainbow bar --> <!-- IF attribution --> <tr> <td> <table class="attribution" width="100%" cellpadding="0" cellspacing="0" border="0" bgcolor="#f8f8f8" style="font-size:18px; color:#777777"> <tr> <td class="attribution_top_spacer" colspan="3" height="21" style="font-size:1px;line-height:1px;"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td> <table width="100%" cellpadding="0" cellspacing="0" border="0" bgcolor="#f8f8f8" style="font-size:18px;color:#777777;"> <tr> <!-- If no avatar do not include profile_image td and set the second div to have a colspan="2" --> <td class="profile_image" width="53" height="40" valign="middle"><img width="40" height="40" src="http://s3.amazonaws.com/pocket-profile-images/b75adba84005d725f236a3f3e27090eb5d6456f.jpg" border="0" style="border-radius: 20px; -moz-border-radius: 20px; -webkit-border-radius: 20px; -ms-border-radius:20px" /></td> <td valign="middle"> <b style="color:#555555">Tim Gallagher</b> shared<span class="with_you"> with you</span>: </td> </tr> </table> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_vertical" colspan="3" height="13" style="font-size:1px;line-height:1px;"> </td> </tr> <!-- IF comment --> <tr> <td class="side_spacer" width="25"> </td> <td class="comment" style="line-height:22px;"> Very exciting and very close to fruition. (Except Theranos.) </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_vertical" colspan="3" height="20" style="font-size:1px;line-height:1px;"> </td> </tr> <!-- ENDIF comment --> <tr> <td height="24" class="caret" colspan="3" bgcolor="white" style="background:white url(http://email-assets.getpocket.com/caretShadow.gif) left top no-repeat;"> <!-- caret / bottom edge --> </td> </tr> </table> </td> </tr> <!-- END IF attribution --> <!-- IF item --> <tr> <td> <table width="100%" cellpadding="0" cellspacing="0" border="0"> <tr> <td class="space_above_title" colspan="3" height="26"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td> <a class="title" href="http://email.getpocket.com/wf/click?upn=taBGH0n3p5fmoPVsUKbIp1Ktne3lZkDom6U43sOc1d6KMo0bPPpYBa0W3hg-2FBsPJ-2FmX5-2F3AJoT85lxypzNZ7w2vEKsK0MbpIRl1Rc0OY6VEQWFmCAjTuwu-2F80x312994EGCX-2FkHGNn4MvtVk77zMXH1ZSbJYSZoLjGxGXE5Zflq6jLdm9YCZLHy7W3rsxQlh_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtgIMHAETSsOzXUJMZvI-2BAQoMu5EsJgu1Ehsyb4Oh2mGZP32-2BPozH9LEtVnzjSLOIJVQSdB-2BH7laELx3TzqMwoS-2F2faMGWwO3zcae-2FeVegKVEVue-2F8yzFg-2BFPlxbC8Ot1ivwGzJJf9JT4xFW5noPU8IQIqgeoNNtRvyOwYimKjqphZonvCK-2BDCo9R-2BVIfgvbekPonFa47OZqzRKcd-2BGsdFAuBNm9oqG9tEdFHZIghsVOE-2BPzXFwAtcVLtPYj-2F172y4Xx3ucnz30UJ51eX1STlSRqm1Nne39ak6Rgtle-2BypwEHEOG2GDcC3GAcmZkDVLfVbQM93-2Bhr5XRT8D51ey-2F1V8hOEAaw4mu6gQzUFbutgBeM-3D" style="font-weight:bold;font-size:22px;color:#3abcb6;">10 Ideas That Are About To Change Medicine Forever</a> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="domain_spacer" colspan="3" height="7" style="font-size:1px;line-height:1px;"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td class="domain"><a style="font-size:16px;color:#999999;text-decoration:none" href="http://email.getpocket.com/wf/click?upn=MaU6wBFc4n7hV5t5EumMPrzzHAIbk3MGRGRGa7bSYGDUKwPQIwlA55MbPvDG76Pt_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtgIMHAETSsOzXUJMZvI-2BAQoMu5EsJgu1Ehsyb4Oh2mGZP32-2BPozH9LEtVnzjSLOIJVQSdB-2BH7laELx3TzqMwoS-2F2faMGWwO3zcae-2FeVegKVEVue-2F8yzFg-2BFPlxbC8Ot1ivwGzJJf9JT4xFW5noPU8IQIqgeoNNtRvyOwYimKjqphZonvCK-2BDCo9R-2BVIfgvbekC8npteJFCEQ0Td2UZDvF-2FMb5WT9r8XzxKPoKsq4GVg8CEyDhjFZudB2ywUtlpHzyCKYMtrxmsnEvWkjnq3wzJBV20OEwsrKeSIY35F2ZGl5iJx-2Fw1ZGc8x4SNgK9yiaCuRojoqXfbu9yswaR2MaSML4jOFuVbbKWq8yIMikEVk8-3D">businessinsider.com</a></td> <td class="side_spacer" width="25"> </td> </tr> <!-- IF quote --> <!-- ENDIF quote --> <tr> <td class="side_spacer" width="25"> </td> <td class="space_above_buttons" colspan="3" height="36"> </td> <td class="side_spacer" width="25"> </td> </tr> </table> </td> </tr> <!-- ENDIF item --> <!-- IF buttons --> <!-- ENDIF buttons --> </table> </td> </tr> </table> <table class="original-only" width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="card_spacer" height="12" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <!-- tile --> <table class="tile prompt_card" width="80%" border="0" cellspacing="0" cellpadding="0" align="center" bgcolor="#ffffff" style="border:1px solid #cdcdcd;border-bottom:2px solid #cdcdcd;max-width:600px;"> <tr> <td class="space_below_buttons" colspan="5" height="30"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td class="prompt_wrapper" colspan="3" style="text-align:center"> <div class="prompt_copy_wrapper" style="line-height:20px;font-size:15px;color:#000000;"> <strong>Don't have time to view this now?</strong><br> Sign up for Pocket and view this page later. </div> <div class="prompt_button_wrapper" style="margin-top:23px;"> <table class="btn" width="175" align="center" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;"> <tr> <td class="t l" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_lt.gif) left top no-repeat;" bgcolor="#ececec"> </td> <td class="t m" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_mt.gif) top repeat-x;" bgcolor="#ececec"> </td> <td class="t r" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rt.gif) right top no-repeat;" bgcolor="#ececec"> </td> </tr> <tr> <td class="l" width="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_ll.gif) left bottom no-repeat;" bgcolor="#ececec"> </td> <td class="m mid" height="26" valign="middle" align="center" style="background:#ececec url(http://email-assets.getpocket.com/btn_m.gif) bottom repeat-x;line-height:normal" bgcolor="#ececec"><a style="color:#2e2e2e;font-weight:bold;font-size:19px;text-shadow:0px 1px #ffffff;text-decoration:none;" href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavZPKhiqxluAcV-2FSL7atKgn4V2VSTYYe40xqbaNd7bmRRnLJQ7odtLte2ezmzN8ND0ued72J0pCZlqgJuJqg0f6wUSwg7Atz-2BSi9jXDh21DI5WwM0FffGWmIIcCedOO81n9ULmyiVw0WCUEZgxMVO-2Fc9RCjDuIy8gUT1lY7OI0xOzxzQYiUOzeqH4MTndM-2B0mlbapYzn6AFWaPVJ-2BjeB9Wt5pIzQDwvTvghKgmLgJucxyk8187wRJUXy1OFnDeT8oHss-2Bl7aehQKTtQuqCqfl1RSv2lavwazibuL5-2FZyMnnG2SdsTBM9ZuT-2FSxvh6mOZp7ThF1W4gPLpezedqmVz8-2FvLoAdSdul1YzbVGrMLmEEltco0ciO4irECDAoBmxXbLaNzcAQBjeUTCa61ydvOkSE9EIgG9-2FwVmds3-2BDvARavRrvNwys-2B4GElipBNiPbYhqs6eLAPp7Wbl08H6b23-2FUx0Mlg-2FXUJvFTLT3Igys2kZaV6OUXyq115dwI7ZzFcfdqLg-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtgIMHAETSsOzXUJMZvI-2BAQoMu5EsJgu1Ehsyb4Oh2mGZP32-2BPozH9LEtVnzjSLOIJVQSdB-2BH7laELx3TzqMwoS-2F2faMGWwO3zcae-2FeVegKVEVue-2F8yzFg-2BFPlxbC8Ot1ivwGzJJf9JT4xFW5noPU8IQIqgeoNNtRvyOwYimKjqphZonvCK-2BDCo9R-2BVIfgvbekgiivYliHgaIpFSoZLSvXYrwP-2FZ-2FZcAkE7S-2B4Hun3gY3XCHtC33j56xrDGg1pUVtEyEnlVuSZPzcuMIJ1XzuBgpZpKLbdm1Ka-2FWMUNnFw0738zRFJhtFQtcD-2Bj65446N7baob7e-2Ft2DACiEcwEEpaS5XXr-2F8HLtz4WZZwG7k-2B48c-3D">Get Pocket</a></td> <td class="r" width="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rr.gif) right bottom no-repeat;" bgcolor="#f8d300"> </td> </tr> <tr> <td class="b l" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_lb.gif) left bottom no-repeat;" bgcolor="#ececec"> </td> <td class="b m" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_mb.gif) bottom repeat-x;" bgcolor="#ececec"> </td> <td class="b r" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rb.gif) right bottom no-repeat;" bgcolor="#ececec"> </td> </tr> </table> </div> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_below_buttons" colspan="5" height="30"> </td> </tr> </table> </td> </tr> </table> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="footer_spacer" height="30" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <table class="footer" width="80%" style="max-width:550px" border="0" cellspacing="0" cellpadding="0" align="center"> <!-- IF footer logo --> <tr> <td align="center"><a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavUDtjNBdtwYQJc3QvCDEkCrb9rN76Px6hs8-2F3pqnF5c4pg9iI5LVq3pjjGjXWyCMbXmEotdp6EMIpfEbaAPyl9AGhktKGI5eVOEidJz8SOwtVYzxPHNU3aZjbBmRUAwaUaVoDYKd71kYdrev96vL5UlMXNA0vwsXNHW4k3dskwqs_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtgIMHAETSsOzXUJMZvI-2BAQoMu5EsJgu1Ehsyb4Oh2mGZP32-2BPozH9LEtVnzjSLOIJVQSdB-2BH7laELx3TzqMwoS-2F2faMGWwO3zcae-2FeVegKVEVue-2F8yzFg-2BFPlxbC8Ot1ivwGzJJf9JT4xFW5noPU8IQIqgeoNNtRvyOwYimKjqphZonvCK-2BDCo9R-2BVIfgvbekvcAxXfes5CJnxLRud66OgLt7BQaFdUHzy7IMvw8FjO-2FqqCk6K5VQyaMlMOCrcRUbHOYEXVj8SECAnzCtk-2Fp2dxSYkEMmNWQao-2BGrs9IU6mOFCqJDIzlF6IoWQioiyHLZZAK8iGUbISoNhIc7pybZoaOgzi7KTlpAznHd5-2FLCBXY-3D"><img class="pocket_embossed" border="0" src="http://email-assets.getpocket.com/pocket_embossed.gif" /></a></td> </tr> <tr> <td class="spacer_around_logo" valign="top" height="24" style="font-size:2px;"> </td> </tr> <!-- ENDIF footer logo --> <tr> <td class="footer_text" valign="top" align="center" style="font-size:11px; line-height:14px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> You are receiving this email because a friend shared to your email address from Pocket.<br/> For support requests, please contact us by going to our <a href="http://email.getpocket.com/wf/click?upn=S10v-2BfWRB4OIigzZ3tVxSzVtvnsL9TD3AibX-2F20JRgU-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtgIMHAETSsOzXUJMZvI-2BAQoMu5EsJgu1Ehsyb4Oh2mGZP32-2BPozH9LEtVnzjSLOIJVQSdB-2BH7laELx3TzqMwoS-2F2faMGWwO3zcae-2FeVegKVEVue-2F8yzFg-2BFPlxbC8Ot1ivwGzJJf9JT4xFW5noPU8IQIqgeoNNtRvyOwYimKjqphZonvCK-2BDCo9R-2BVIfgvbek9PxbEvb4oVXeIS-2BqoXf5ri1Xp8AwgA-2B3Ev1g1-2Bmhf-2BMOwNMX-2Bl3snxwqRqZHO6Alv2DiD9fuNuiyb2iRSE9V62bbmjp2XUj0g1LdhM2TtQdOm19-2B84ez-2FvjymH09mY1U7PyxBWS0oxdKOIgSe6EvKyqrI-2BV5GavsOmE93s-2F7ZDk-3D" style="color:#666666; text-decoration:underline;">support page</a>. </td> </tr> <tr class="original-only"> <td valign="top" height="22" style="font-size:2px;"> </td> </tr> <tr class="original-only"> <td valign="top" align="center"> <table width="275" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top" align="right"> <a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavVvGMXLmRUQyPiGcf9i1vP-2BNbnTDS4YteJHmstp2XC0tyoS9FFtF-2FJFsA-2BTewSIn5TLy7dru5f7PkYBO14UskpHU7PWd8qiSlGCuEgIZqxWTpKlW5WbehjdDG1A0S8W99wrmJVoyl2mzVyUQP2RyuFK-2BwZGLc9EbTSu1lFKO-2BuqveIl65tAxQuaQLwU3kAvTbw-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtgIMHAETSsOzXUJMZvI-2BAQoMu5EsJgu1Ehsyb4Oh2mGZP32-2BPozH9LEtVnzjSLOIJVQSdB-2BH7laELx3TzqMwoS-2F2faMGWwO3zcae-2FeVegKVEVue-2F8yzFg-2BFPlxbC8Ot1ivwGzJJf9JT4xFW5noPU8IQIqgeoNNtRvyOwYimKjqphZonvCK-2BDCo9R-2BVIfgvbekrcp7yy6NbNGdBi24otJYI-2B1tF8erO4KZ-2F4Ejc1JNfSq6o1NI-2FFI-2BQtknBbLK1m8kqHWrAJ2c-2F7-2B8K4XoxbpYDVNBpyQkTgBNebJDoX1J-2B7zYrVMwHUSEGabIdUwtPNND1sHeduUP-2BdU0O179-2BV1RmsPAvewqkNCL6gPVnkA74U0-3D" style="font-size:11px;font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;font-weight:bold;text-decoration:underline;"> Notification Settings </a> </td> <td valign="middle" align="center"> <img alt="" width="13" src="http://email-assets.getpocket.com/sep01-original.gif" /> </td> <td valign="top" align="left"> <a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavbym7-2ByxEzk5R-2FyNUsaZglMddz-2BpXt-2By6jyn3dtrmRxWKVonHrdXar4iqDYX70FEuy4tkqJDIq7aJkC9sTBnl11BeRkE6VgkcuZ5loB4VV5StnZpHe1n5J54L8Um3EHpwf004msleTgWdwcWOn-2Bp47zoOhPcNP0IMJof-2FKFesfAAdEEb5NdGHq1g24EmjrVSIw-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtgIMHAETSsOzXUJMZvI-2BAQoMu5EsJgu1Ehsyb4Oh2mGZP32-2BPozH9LEtVnzjSLOIJVQSdB-2BH7laELx3TzqMwoS-2F2faMGWwO3zcae-2FeVegKVEVue-2F8yzFg-2BFPlxbC8Ot1ivwGzJJf9JT4xFW5noPU8IQIqgeoNNtRvyOwYimKjqphZonvCK-2BDCo9R-2BVIfgvbekHtndCLdB2jeTU6WFImv5rBM3uc6JcFND1IQqqtA-2F7-2B6MUOas0iVVoF7r04QeRgNQJZUe1TC8Q2QUEpI9-2FFXf1QPwwjQyOYu2DKKTjBQ-2BjoJW7S13NshKOEQ0D67uSB-2B188cGEEgYpOaw39NpppCXX-2Fy8i0xcY86LLDjmY1UQPP4-3D" style="font-size:11px;font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;font-weight:bold;text-decoration:underline;"> Privacy Policy </a> </td> </tr> </table> </td> </tr> <tr> <td valign="top" height="32" style="font-size:2px;"> </td> </tr> <tr> <td valign="top" align="center"> <font style="font-size:10px; line-height:12px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> Read It Later, Inc., 731 Market Street Suite 410, San Francisco, CA 94108, USA </font> </td> </tr> <tr> <td valign="top" height="10" style="font-size:2px;"> </td> </tr> <tr> <td valign="top" align="center"> <font style="font-size:10px; line-height:12px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> © 2013 Read It Later, Inc. All Rights Reserved. </font> </td> </tr> <tr> <td valign="top" height="30" style="font-size:2px;"> </td> </tr> </table> </td> </tr> </table> <img src="http://email.getpocket.com/wf/open?upn=5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtgIMHAETSsOzXUJMZvI-2BAQoMu5EsJgu1Ehsyb4Oh2mGZP32-2BPozH9LEtVnzjSLOIJVQSdB-2BH7laELx3TzqMwoS-2F2faMGWwO3zcae-2FeVegKVEVue-2F8yzFg-2BFPlxbC8Ot1ivwGzJJf9JT4xFW5noPU8IQIqgeoNNtRvyOwYimKjqphTBkGqBZscGbCAuUtBhqQHYb-2B9Lz9CnIAKYBmstwRZAJY-2F5KNaEozOOsD4GooE4xwOsIfL6JUB28DzR4slR16l1RXaGQeZBXVthaXVnmy53x78aRHJtoAGav0ZJ4vfrB9lI4BhbJjQozWuoSSmCryNLfKL8ov91241n-2BnSdP10VJdFSNEC-2BBP-2FF1cUugtPyC4YJQFS6Yseb9Cv0xWoFbq9" alt="" width="1" height="1" border="0" style="height:1px !important;width:1px !important;border-width:0 !important;margin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;margin-left:0 !important;padding-top:0 !important;padding-bottom:0 !important;padding-right:0 !important;padding-left:0 !important;"/> TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-10808176467737921432014-03-12T13:51:00.001-04:002014-03-12T13:51:08.437-04:00Tim Gallagher shared an article from Pocket: Pharmaceutical Scouts Seek New Star Drugs for Cancer, Diabetes<!-- outer container --> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="top_spacer" height="10" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <!-- tile --> <table class="tile" width="80%" border="0" cellspacing="0" cellpadding="0" align="center" bgcolor="#ffffff" style="border:1px solid #cdcdcd;border-bottom:2px solid #cdcdcd;max-width:600px;min-width:300px;"> <!-- IF rainbow bar --> <!-- ENDIF rainbow bar --> <!-- IF attribution --> <tr> <td> <table class="attribution" width="100%" cellpadding="0" cellspacing="0" border="0" bgcolor="#f8f8f8" style="font-size:18px; color:#777777"> <tr> <td class="attribution_top_spacer" colspan="3" height="21" style="font-size:1px;line-height:1px;"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td> <table width="100%" cellpadding="0" cellspacing="0" border="0" bgcolor="#f8f8f8" style="font-size:18px;color:#777777;"> <tr> <!-- If no avatar do not include profile_image td and set the second div to have a colspan="2" --> <td class="profile_image" width="53" height="40" valign="middle"><img width="40" height="40" src="http://s3.amazonaws.com/pocket-profile-images/b75adba84005d725f236a3f3e27090eb5d6456f.jpg" border="0" style="border-radius: 20px; -moz-border-radius: 20px; -webkit-border-radius: 20px; -ms-border-radius:20px" /></td> <td valign="middle"> <b style="color:#555555">Tim Gallagher</b> shared<span class="with_you"> with you</span>: </td> </tr> </table> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_vertical" colspan="3" height="13" style="font-size:1px;line-height:1px;"> </td> </tr> <!-- IF comment --> <tr> <td class="side_spacer" width="25"> </td> <td class="comment" style="line-height:22px;"> Here's a view inside drug partnering, with the main point being that Big Pharma is much more open to collaboration. That isn't news to most, but still good personal insights in the article. I'm surprised, though at one of the stats in the article: 33% of all Big Pharma leads are in-licensed. Put another way, 2/3rds of all Big Pharma programs are still internally sourced. That doesn't seem right - internal discovery in Big Pharma seems to me to have shrunken to a minority activity - maybe 25% of all big Pharma R&D. What's your impression? </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_vertical" colspan="3" height="20" style="font-size:1px;line-height:1px;"> </td> </tr> <!-- ENDIF comment --> <tr> <td height="24" class="caret" colspan="3" bgcolor="white" style="background:white url(http://email-assets.getpocket.com/caretShadow.gif) left top no-repeat;"> <!-- caret / bottom edge --> </td> </tr> </table> </td> </tr> <!-- END IF attribution --> <!-- IF item --> <tr> <td> <table width="100%" cellpadding="0" cellspacing="0" border="0"> <tr> <td class="space_above_title" colspan="3" height="26"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td> <a class="title" href="http://email.getpocket.com/wf/click?upn=taBGH0n3p5fmoPVsUKbIp1P5CUSCCWxKvXswMjsVBtP8DdTGNebnW8sdM102oN3EZ-2B-2FLLcr8v-2B7WSZHQ1qeAQPeY7ixqpKDsukJyU1GAke-2FWgx0VnSi0xE5b-2B-2FsMC5g08prwsMPLmomI48oc08AA9EmA-2FjRR0Ai0Dg4sufeQ3RKxj-2BLuQITckMhIB6USSUFu_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtqhD1EqmJwfmCa7yVRGMe6FKLF3ijC17pmUWHL5yoJ4bzueznOLc1QGxDtZ6JpufvtGMz-2Bf-2FwngCf4c3NrvbSBW4CCkKKmSZ-2BIT5TbYjUumb7gFTtmQ9t7fBRG-2BeFqFqpE6VD66VT1W-2FralAvSq-2BbafB-2FZ2ZZErnxxXT5fmLWQObvr6Jq6QTWEduMqNJyfd5ONqX7HzSe7-2F8kkxWWyqWeVIQFI6PH4C6j9teJuwgMgQH9-2FynoD3amzTLPjdYB7Z3JvrZN3rl1DgIdPsDkYU5BtIo-2BhrD09vwDAVuSUdNiPteHX9c-2BgYtleAO858yzIRhY4GHVIrc0s8Q0Kx7xE6DnVH81yH-2FkFY8qwTCHKvSNhOx6r7o6uuRr5Zda96X-2FmdaO" style="font-weight:bold;font-size:22px;color:#3abcb6;">Pharmaceutical Scouts Seek New Star Drugs for Cancer, Diabetes</a> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="domain_spacer" colspan="3" height="7" style="font-size:1px;line-height:1px;"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td class="domain"><a style="font-size:16px;color:#999999;text-decoration:none" href="http://email.getpocket.com/wf/click?upn=IghCXq84ni7JBynzptyyeOp3u1Plj8bjnfkfFFh-2B6OE-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtqhD1EqmJwfmCa7yVRGMe6FKLF3ijC17pmUWHL5yoJ4bzueznOLc1QGxDtZ6JpufvtGMz-2Bf-2FwngCf4c3NrvbSBW4CCkKKmSZ-2BIT5TbYjUumb7gFTtmQ9t7fBRG-2BeFqFqpE6VD66VT1W-2FralAvSq-2BbafB-2FZ2ZZErnxxXT5fmLWQObvr6Jq6QTWEduMqNJyfd5OZdaR9ncxkT7fwn-2FHkJAuADzoz20ktJamliV51HF9GPNLrrzAYtZoyy-2BrvStVlCv3f1XhZM8ZP537a4IbdSeOTCFVJb9N0tx5dNyMYi4sh2vcSohZDAziOJYzZL-2BKhZTGzlnnjuX1H5jQF3bRMzThPh-2B5NSrJRxAwusvBUNMlwjvYf-2FbB7uUf-2FM3FIxR4DHw1">online.wsj.com</a></td> <td class="side_spacer" width="25"> </td> </tr> <!-- IF quote --> <!-- ENDIF quote --> <tr> <td class="side_spacer" width="25"> </td> <td class="space_above_buttons" colspan="3" height="36"> </td> <td class="side_spacer" width="25"> </td> </tr> </table> </td> </tr> <!-- ENDIF item --> <!-- IF buttons --> <!-- ENDIF buttons --> </table> </td> </tr> </table> <table class="original-only" width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="card_spacer" height="12" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <!-- tile --> <table class="tile prompt_card" width="80%" border="0" cellspacing="0" cellpadding="0" align="center" bgcolor="#ffffff" style="border:1px solid #cdcdcd;border-bottom:2px solid #cdcdcd;max-width:600px;"> <tr> <td class="space_below_buttons" colspan="5" height="30"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td class="prompt_wrapper" colspan="3" style="text-align:center"> <div class="prompt_copy_wrapper" style="line-height:20px;font-size:15px;color:#000000;"> <strong>Don't have time to view this now?</strong><br> Sign up for Pocket and view this page later. </div> <div class="prompt_button_wrapper" style="margin-top:23px;"> <table class="btn" width="175" align="center" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;"> <tr> <td class="t l" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_lt.gif) left top no-repeat;" bgcolor="#ececec"> </td> <td class="t m" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_mt.gif) top repeat-x;" bgcolor="#ececec"> </td> <td class="t r" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rt.gif) right top no-repeat;" bgcolor="#ececec"> </td> </tr> <tr> <td class="l" width="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_ll.gif) left bottom no-repeat;" bgcolor="#ececec"> </td> <td class="m mid" height="26" valign="middle" align="center" style="background:#ececec url(http://email-assets.getpocket.com/btn_m.gif) bottom repeat-x;line-height:normal" bgcolor="#ececec"><a style="color:#2e2e2e;font-weight:bold;font-size:19px;text-shadow:0px 1px #ffffff;text-decoration:none;" href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavZPKhiqxluAcV-2FSL7atKgn67B1OKcIIa-2BaOxJCbyeAZRpjimz3QaUhvfYndhIHiv2ECK6CvOot4li4Teg6cC8RuV6QTaq6pbEmE1Fo-2Be-2Bf9x4b2OuEgQwkKuk5Qn3E-2FYSu2W0QK7w-2Br8mwZ4QGac5RHsAUTtQGDpjrq4wpso7FxexA-2FUHLzkXFloi-2Bwi61OTz6OqV7B89sZjZn5IBE01KIYVovLOwiLc2JLWaIXzV9uGN4PkHa9uoN4HOOxM5MX9qpDXFL2BYQXoGAwUZfo4P-2BBpPMefcTveNAcWEGJQnGR32d-2FWYv7a3HJRe4TuHbW35MZu3R5SD9dgny83cM-2BBzCJtQ8RRd4ACqQUhBWntNmlyTKUqyY4UlziJgOVHCQKIcvU4riUa5YrqBoKOowsX6wutO2-2BYxNh5zTXQhgK43qym4pnyHjhRGXPRVrHGTeT2-2FK0QpDlTnNOPm6pQuzK8QSdf8DjTDRLYZ-2Fms3hpNJhTR-2BKNtq7FyuBulLVaZF6tP5w-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtqhD1EqmJwfmCa7yVRGMe6FKLF3ijC17pmUWHL5yoJ4bzueznOLc1QGxDtZ6JpufvtGMz-2Bf-2FwngCf4c3NrvbSBW4CCkKKmSZ-2BIT5TbYjUumb7gFTtmQ9t7fBRG-2BeFqFqpE6VD66VT1W-2FralAvSq-2BbafB-2FZ2ZZErnxxXT5fmLWQObvr6Jq6QTWEduMqNJyfd5OdsvfxETaO91NCLI2gc6Ntf5zqGx-2BBw-2BQWQxGT0ONtOF2ng0UvVT9obg1rViXS-2FDYJoHynnXPXyMaX3Rqf412dy6zJSJagy2bYV-2B1j8sxtOT9fGeMe1UeUgL6iU4SGj4tsMRLg8t9gvUMfOaPf8t13THxI0B9Rj3F4d49-2BWtCTnYq5y7HwEPRuaTThilhrdMG">Get Pocket</a></td> <td class="r" width="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rr.gif) right bottom no-repeat;" bgcolor="#f8d300"> </td> </tr> <tr> <td class="b l" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_lb.gif) left bottom no-repeat;" bgcolor="#ececec"> </td> <td class="b m" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_mb.gif) bottom repeat-x;" bgcolor="#ececec"> </td> <td class="b r" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rb.gif) right bottom no-repeat;" bgcolor="#ececec"> </td> </tr> </table> </div> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_below_buttons" colspan="5" height="30"> </td> </tr> </table> </td> </tr> </table> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="footer_spacer" height="30" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <table class="footer" width="80%" style="max-width:550px" border="0" cellspacing="0" cellpadding="0" align="center"> <!-- IF footer logo --> <tr> <td align="center"><a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavUDtjNBdtwYQJc3QvCDEkCrb9rN76Px6hs8-2F3pqnF5c4pg9iI5LVq3pjjGjXWyCMbXmEotdp6EMIpfEbaAPyl9AGhktKGI5eVOEidJz8SOwtVYzxPHNU3aZjbBmRUAwaUaVoDYKd71kYdrev96vL5UlMXNA0vwsXNHW4k3dskwqs_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtqhD1EqmJwfmCa7yVRGMe6FKLF3ijC17pmUWHL5yoJ4bzueznOLc1QGxDtZ6JpufvtGMz-2Bf-2FwngCf4c3NrvbSBW4CCkKKmSZ-2BIT5TbYjUumb7gFTtmQ9t7fBRG-2BeFqFqpE6VD66VT1W-2FralAvSq-2BbafB-2FZ2ZZErnxxXT5fmLWQObvr6Jq6QTWEduMqNJyfd5OtrkGqGPB4AgmrtxCCQaWaemmA7PQuwvtco2LlOX5o8jtyxkLpEBaa2l1qMhFKSQ4GVmXW8xEwYrcdRvWX6vsEFicHrubE0ozSqWk1dmJBYDzK8FVqcYBjK4Sd23-2FWZSD0t6uZsZjn2hAzLCvSic-2FfUSxG9XXJp-2FrfzS3ci6c2o57yQA1Wsr-2BL54afwqLjFDa"><img class="pocket_embossed" border="0" src="http://email-assets.getpocket.com/pocket_embossed.gif" /></a></td> </tr> <tr> <td class="spacer_around_logo" valign="top" height="24" style="font-size:2px;"> </td> </tr> <!-- ENDIF footer logo --> <tr> <td class="footer_text" valign="top" align="center" style="font-size:11px; line-height:14px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> You are receiving this email because a friend shared to your email address from Pocket.<br/> For support requests, please contact us by going to our <a href="http://email.getpocket.com/wf/click?upn=S10v-2BfWRB4OIigzZ3tVxSzVtvnsL9TD3AibX-2F20JRgU-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtqhD1EqmJwfmCa7yVRGMe6FKLF3ijC17pmUWHL5yoJ4bzueznOLc1QGxDtZ6JpufvtGMz-2Bf-2FwngCf4c3NrvbSBW4CCkKKmSZ-2BIT5TbYjUumb7gFTtmQ9t7fBRG-2BeFqFqpE6VD66VT1W-2FralAvSq-2BbafB-2FZ2ZZErnxxXT5fmLWQObvr6Jq6QTWEduMqNJyfd5OOm8jw6FJsjBZPGswLGIGnezkOgHYuiYeaPcpAvnaCyN5tOEnRUb8svPWAzuKoPh7EpchDfd0gjnnXFH7-2FwMpBMU2xiemKKIeynuwZ0ZovIIl3T4Sx4aSkWBNLsOKqFbQIxcDhuP5nY-2F45ypupOZnGUzyq5BYSvO0-2F1PWXaEMTmoe2PCHig9qFpNTYoyirMCR" style="color:#666666; text-decoration:underline;">support page</a>. </td> </tr> <tr class="original-only"> <td valign="top" height="22" style="font-size:2px;"> </td> </tr> <tr class="original-only"> <td valign="top" align="center"> <table width="275" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top" align="right"> <a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavVvGMXLmRUQyPiGcf9i1vP-2BNbnTDS4YteJHmstp2XC0tyoS9FFtF-2FJFsA-2BTewSIn5TLy7dru5f7PkYBO14UskpHU7PWd8qiSlGCuEgIZqxWTpKlW5WbehjdDG1A0S8W99wrmJVoyl2mzVyUQP2RyuFK-2BwZGLc9EbTSu1lFKO-2BuqveIl65tAxQuaQLwU3kAvTbw-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtqhD1EqmJwfmCa7yVRGMe6FKLF3ijC17pmUWHL5yoJ4bzueznOLc1QGxDtZ6JpufvtGMz-2Bf-2FwngCf4c3NrvbSBW4CCkKKmSZ-2BIT5TbYjUumb7gFTtmQ9t7fBRG-2BeFqFqpE6VD66VT1W-2FralAvSq-2BbafB-2FZ2ZZErnxxXT5fmLWQObvr6Jq6QTWEduMqNJyfd5OhlSWQ-2B3VKmQvu3P4XqeZKvtIUEgK-2BHMzHZ7IHzeGHLE4V1qDIYhoDNLB-2FISsYWX6e4RuEyIMXWpBuH9-2BT7GtC1hqtmCJQaqzCh6WuW7R9xOtAYBBJ5-2BF5KPFncVi-2FMiFCa06bEOpPzn8rPmAQeynXNVdHS0GHtzyvLaPMMCJoQja6udooeFYascyva5g8exX" style="font-size:11px;font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;font-weight:bold;text-decoration:underline;"> Notification Settings </a> </td> <td valign="middle" align="center"> <img alt="" width="13" src="http://email-assets.getpocket.com/sep01-original.gif" /> </td> <td valign="top" align="left"> <a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavbym7-2ByxEzk5R-2FyNUsaZglMddz-2BpXt-2By6jyn3dtrmRxWKVonHrdXar4iqDYX70FEuy4tkqJDIq7aJkC9sTBnl11BeRkE6VgkcuZ5loB4VV5StnZpHe1n5J54L8Um3EHpwf004msleTgWdwcWOn-2Bp47zoOhPcNP0IMJof-2FKFesfAAdEEb5NdGHq1g24EmjrVSIw-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtqhD1EqmJwfmCa7yVRGMe6FKLF3ijC17pmUWHL5yoJ4bzueznOLc1QGxDtZ6JpufvtGMz-2Bf-2FwngCf4c3NrvbSBW4CCkKKmSZ-2BIT5TbYjUumb7gFTtmQ9t7fBRG-2BeFqFqpE6VD66VT1W-2FralAvSq-2BbafB-2FZ2ZZErnxxXT5fmLWQObvr6Jq6QTWEduMqNJyfd5O7yNPq0M0HFkmzoU4YDnx8P-2FticitLNIXdlTkKILqesYGYjbvHN9NbEHbCEOTjmtEw6DHDCUBcMu56DUlz5Zv3F1pQ0d8jGLhBE5BQJpMUR0MxwvpSez9sbt8X-2FAuh3i2-2FeGlP8OmGAUk0AOPy2alaJLUoEt3hAB6P5e-2BMWB4FyUSEzWQhWNjPivio0PhWf8z" style="font-size:11px;font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;font-weight:bold;text-decoration:underline;"> Privacy Policy </a> </td> </tr> </table> </td> </tr> <tr> <td valign="top" height="32" style="font-size:2px;"> </td> </tr> <tr> <td valign="top" align="center"> <font style="font-size:10px; line-height:12px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> Read It Later, Inc., 731 Market Street Suite 410, San Francisco, CA 94108, USA </font> </td> </tr> <tr> <td valign="top" height="10" style="font-size:2px;"> </td> </tr> <tr> <td valign="top" align="center"> <font style="font-size:10px; line-height:12px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> © 2013 Read It Later, Inc. All Rights Reserved. </font> </td> </tr> <tr> <td valign="top" height="30" style="font-size:2px;"> </td> </tr> </table> </td> </tr> </table> <img src="http://email.getpocket.com/wf/open?upn=5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtqhD1EqmJwfmCa7yVRGMe6FKLF3ijC17pmUWHL5yoJ4bzueznOLc1QGxDtZ6JpufvtGMz-2Bf-2FwngCf4c3NrvbSBW4CCkKKmSZ-2BIT5TbYjUumb7gFTtmQ9t7fBRG-2BeFqFqpE6VD66VT1W-2FralAvSq-2BbafB-2FZ2ZZErnxxXT5fmLWQObvr6Jq6QTWEduMqNJyfd5OwXBQdl4BJhpcRQMNrrt3RJzMmsDYr9ALoXhz7jDZYADOUkbhxG-2BQ4DiyOGM6z31rhuLUjqOY9-2FFdURlzt9p8Kz0qmOlOnMn3q6CxDHhwMwSGht6yidyr5kYSLT-2B1kPHasuolyGhWEn70Js-2BN6HA1bsIfQevrr-2FFlES6EpzlCRE5qB-2FNg-2B1q7mVl-2FmsI8XNSg" alt="" width="1" height="1" border="0" style="height:1px !important;width:1px !important;border-width:0 !important;margin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;margin-left:0 !important;padding-top:0 !important;padding-bottom:0 !important;padding-right:0 !important;padding-left:0 !important;"/> TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-43988518738058307702014-02-25T13:02:00.001-05:002014-02-25T13:02:06.673-05:00Molecular Diagnostics Are in a Rut. The Industry Needs the FDA<!-- outer container --> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="top_spacer" height="10" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <!-- tile --> <table class="tile" width="80%" border="0" cellspacing="0" cellpadding="0" align="center" bgcolor="#ffffff" style="border:1px solid #cdcdcd;border-bottom:2px solid #cdcdcd;max-width:600px;min-width:300px;"> <!-- IF rainbow bar --> <!-- ENDIF rainbow bar --> <!-- IF attribution --> <tr> <td> <table class="attribution" width="100%" cellpadding="0" cellspacing="0" border="0" bgcolor="#f8f8f8" style="font-size:18px; color:#777777"> <tr> <td class="attribution_top_spacer" colspan="3" height="21" style="font-size:1px;line-height:1px;"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td> <table width="100%" cellpadding="0" cellspacing="0" border="0" bgcolor="#f8f8f8" style="font-size:18px;color:#777777;"> <tr> <!-- If no avatar do not include profile_image td and set the second div to have a colspan="2" --> <td class="profile_image" width="53" height="40" valign="middle"><img width="40" height="40" src="http://s3.amazonaws.com/pocket-profile-images/b75adba84005d725f236a3f3e27090eb5d6456f.jpg" border="0" style="border-radius: 20px; -moz-border-radius: 20px; -webkit-border-radius: 20px; -ms-border-radius:20px" /></td> <td valign="middle"> <b style="color:#555555">Tim Gallagher</b> shared<span class="with_you"> with you</span>: </td> </tr> </table> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_vertical" colspan="3" height="13" style="font-size:1px;line-height:1px;"> </td> </tr> <!-- IF comment --> <tr> <td class="side_spacer" width="25"> </td> <td class="comment" style="line-height:22px;"> A good look at the muddled state of molecular diagnostics. </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_vertical" colspan="3" height="20" style="font-size:1px;line-height:1px;"> </td> </tr> <!-- ENDIF comment --> <tr> <td height="24" class="caret" colspan="3" bgcolor="white" style="background:white url(http://email-assets.getpocket.com/caretShadow.gif) left top no-repeat;"> <!-- caret / bottom edge --> </td> </tr> </table> </td> </tr> <!-- END IF attribution --> <!-- IF item --> <tr> <td> <table width="100%" cellpadding="0" cellspacing="0" border="0"> <tr> <td class="space_above_title" colspan="3" height="26"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td> <a class="title" href="http://email.getpocket.com/wf/click?upn=taBGH0n3p5fmoPVsUKbIpzYW2D1y6JgepCYE2-2BTUpBXSHLW0Oc-2FrtiM-2FmJvv0bxuZ21UBx-2FFj51QTDkSebtSBb5HzomBmkPQJqE9xskcw23T9Pi-2BOOcd0-2FvaCh1KUfVFhDS6wQ5V3lro6AbOh78XEq1EpaWNVVv2kTd4X9LcSXYTXFZavfFScq0JD96uZxrC_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt-2F1A1L7-2BfjpfZI6-2BRSl8rc2bxhHKWHNtT9kzkEy0cY5e18rdZ-2B9tZb0gspLSkL7Lo2kYNIKM3R0wY4-2FEBgnQI-2BK4imuk65F7484zy4E-2B0dWtunhFwvQ-2FkLIGT77DrQKHQ6BtRyWkqz6jWUBMWLb1gJzndywBGIsXr1S5icF3Gvb9tiwx4lGg82dTYw3tc1sJk5xHheyrvdn84N15wgiO-2BUOUh1kp-2F84BL2YHiHbfUuzQECT5UuFNsWnhV7FWKCHTmfGQG3uQLtcEEMAjlqyE79fZrPYLEwESSiMlFlsK27ttBHE88zsWxKZH9uLaanDUwDLfuA1BwEBAqqK4KzytjoFr2KqqKdvQ7QHLmIYREWqzplEM7zo-2FnxAq9RaHL5agC" style="font-weight:bold;font-size:22px;color:#3abcb6;">Molecular Diagnostics Are in a Rut. The Industry Needs the FDA</a> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="domain_spacer" colspan="3" height="7" style="font-size:1px;line-height:1px;"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td class="domain"><a style="font-size:16px;color:#999999;text-decoration:none" href="http://email.getpocket.com/wf/click?upn=mdBKml5jOijqk-2BNftnw9x9QTJ-2BIrzoyTccJb90i8XzU-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt-2F1A1L7-2BfjpfZI6-2BRSl8rc2bxhHKWHNtT9kzkEy0cY5e18rdZ-2B9tZb0gspLSkL7Lo2kYNIKM3R0wY4-2FEBgnQI-2BK4imuk65F7484zy4E-2B0dWtunhFwvQ-2FkLIGT77DrQKHQ6BtRyWkqz6jWUBMWLb1gJzndywBGIsXr1S5icF3Gvb9tiwx4lGg82dTYw3tc1sJku39N-2B-2FcsWTKSsql-2FnNyTpvij94RnHKdT0BlbR42tqhfnASNyBdvrCsPSmVeC3av69OwBjEAkIOHRBjMCawbRYOzxL8rKD51kCHBa5thm9YFqqORU2LaP-2Bny8ZmbAxOM03Lr-2BvLX9TCKMEg2xkJZcP4sjP77IdbOmiZ1WcKhcsYDINdQXaLYkyyUOJl6vZZrW">xconomy.com</a></td> <td class="side_spacer" width="25"> </td> </tr> <!-- IF quote --> <!-- ENDIF quote --> <tr> <td class="side_spacer" width="25"> </td> <td class="space_above_buttons" colspan="3" height="36"> </td> <td class="side_spacer" width="25"> </td> </tr> </table> </td> </tr> <!-- ENDIF item --> <!-- IF buttons --> <!-- ENDIF buttons --> </table> </td> </tr> </table> <table class="original-only" width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="card_spacer" height="12" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <!-- tile --> <table class="tile prompt_card" width="80%" border="0" cellspacing="0" cellpadding="0" align="center" bgcolor="#ffffff" style="border:1px solid #cdcdcd;border-bottom:2px solid #cdcdcd;max-width:600px;"> <tr> <td class="space_below_buttons" colspan="5" height="30"> </td> </tr> <tr> <td class="side_spacer" width="25"> </td> <td class="prompt_wrapper" colspan="3" style="text-align:center"> <div class="prompt_copy_wrapper" style="line-height:20px;font-size:15px;color:#000000;"> <strong>Don't have time to view this now?</strong><br> Sign up for Pocket and view this page later. </div> <div class="prompt_button_wrapper" style="margin-top:23px;"> <table class="btn" width="175" align="center" cellpadding="0" cellspacing="0" border="0" style="border-collapse:collapse;"> <tr> <td class="t l" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_lt.gif) left top no-repeat;" bgcolor="#ececec"> </td> <td class="t m" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_mt.gif) top repeat-x;" bgcolor="#ececec"> </td> <td class="t r" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rt.gif) right top no-repeat;" bgcolor="#ececec"> </td> </tr> <tr> <td class="l" width="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_ll.gif) left bottom no-repeat;" bgcolor="#ececec"> </td> <td class="m mid" height="26" valign="middle" align="center" style="background:#ececec url(http://email-assets.getpocket.com/btn_m.gif) bottom repeat-x;line-height:normal" bgcolor="#ececec"><a style="color:#2e2e2e;font-weight:bold;font-size:19px;text-shadow:0px 1px #ffffff;text-decoration:none;" href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavZPKhiqxluAcV-2FSL7atKgn5NwVGn8BaS0onFL-2BdJFCpyUuH7HtnrJOjvTmFuZm2b-2B2tBmEClHmplfnOeKpuegQrHe-2BVbkwJtiI-2BoAembudB1ANU5ckaIco-2BPc-2FJ0KsDL2KVr4RCRZPIkU8jT4KAdgsVgrTCM3m-2FVNOd-2FfsELgPnapUREQGh5bUWrDlYkpeqI08hhXp71gkW-2B9GLjUHqNmVfoa3yN-2Fa5JOkjgPSZxRQlmQhWmNbpqwfMmW7XYMX-2Fqpf1I8h7Ik-2FDj4tNEEbKBXkFAblJnp406ovQ90Mgd6ZPw75zWDLOJE7-2FoI1uLNdzSt-2FL0Gr-2FlEkrpb90ENd6Ei8pUZ44LOhzMaMgrhkIIjiWoq7mHl-2B6VfDVJXNJ7pNxeLQ5fRWU7apNpBpgUjC6J1VunYThn-2FPbs632HM-2FBY4eKX4w1w-2Fe0Pe3wVubaEfIamKOYp-2F3-2F8XVROrEGJ5sGTumtG2O8KckzTvCM4yKnOXGW5sn-2FJhZHQbMAgungoJnGDNQ-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt-2F1A1L7-2BfjpfZI6-2BRSl8rc2bxhHKWHNtT9kzkEy0cY5e18rdZ-2B9tZb0gspLSkL7Lo2kYNIKM3R0wY4-2FEBgnQI-2BK4imuk65F7484zy4E-2B0dWtunhFwvQ-2FkLIGT77DrQKHQ6BtRyWkqz6jWUBMWLb1gJzndywBGIsXr1S5icF3Gvb9tiwx4lGg82dTYw3tc1sJkiZ8Wq6YixM2KpWxbnGYyHKqs-2BayEMsmxi3R4HazSBaLSWeWldO9NEjarbTV6nGMiiI5uIngncTv1H-2F5IRNZlCHNjUJYsbQ33oKksuswlb-2FkqmUCcdMlfF1-2BnxyEHJfOMtN1DnxY5h9aoqCBXIX5FnACG0Rut2-2BXngeGBt8c47NWthNWpv8v7TaaFL8TUa1aR">Get Pocket</a></td> <td class="r" width="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rr.gif) right bottom no-repeat;" bgcolor="#f8d300"> </td> </tr> <tr> <td class="b l" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_lb.gif) left bottom no-repeat;" bgcolor="#ececec"> </td> <td class="b m" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_mb.gif) bottom repeat-x;" bgcolor="#ececec"> </td> <td class="b r" width="7" height="7" style="font-size:1px;line-height:1px;background:#ececec url(http://email-assets.getpocket.com/btn_rb.gif) right bottom no-repeat;" bgcolor="#ececec"> </td> </tr> </table> </div> </td> <td class="side_spacer" width="25"> </td> </tr> <tr> <td class="space_below_buttons" colspan="5" height="30"> </td> </tr> </table> </td> </tr> </table> <table width="100%" border="0" cellspacing="0" cellpadding="0" style="table-layout:fixed;font-family:Helvetica,Arial,sans-serif;background:#efefef" bgcolor="#efefef"> <tr> <td class="footer_spacer" height="30" style="font-size:1px"> </td> </tr> <tr> <td valign="top"> <table class="footer" width="80%" style="max-width:550px" border="0" cellspacing="0" cellpadding="0" align="center"> <!-- IF footer logo --> <tr> <td align="center"><a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavUDtjNBdtwYQJc3QvCDEkCrb9rN76Px6hs8-2F3pqnF5c4pg9iI5LVq3pjjGjXWyCMbXmEotdp6EMIpfEbaAPyl9AGhktKGI5eVOEidJz8SOwtVYzxPHNU3aZjbBmRUAwaUaVoDYKd71kYdrev96vL5UlMXNA0vwsXNHW4k3dskwqs_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt-2F1A1L7-2BfjpfZI6-2BRSl8rc2bxhHKWHNtT9kzkEy0cY5e18rdZ-2B9tZb0gspLSkL7Lo2kYNIKM3R0wY4-2FEBgnQI-2BK4imuk65F7484zy4E-2B0dWtunhFwvQ-2FkLIGT77DrQKHQ6BtRyWkqz6jWUBMWLb1gJzndywBGIsXr1S5icF3Gvb9tiwx4lGg82dTYw3tc1sJkI8glXGLG-2BznLblNZuRYufC93yMG00kIyzhipBVMGJYOELIJ-2FzYJKVXgz9fh5bz4frHQ9XUxU7BPIxpkp-2FxQT-2FmXA4C8p8Dv9cdVdG1Ipf2qC-2FcbBlEhf47FFmLqx1k9vOyZw7o-2FyZHphB-2BYA6uqQ48NiiD68dEP5k7VA60SL1VOrJONhLV7l-2B-2BHrhVMDfXC2"><img class="pocket_embossed" border="0" src="http://email-assets.getpocket.com/pocket_embossed.gif" /></a></td> </tr> <tr> <td class="spacer_around_logo" valign="top" height="24" style="font-size:2px;"> </td> </tr> <!-- ENDIF footer logo --> <tr> <td class="footer_text" valign="top" align="center" style="font-size:11px; line-height:14px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> You are receiving this email because a friend shared to your email address from Pocket.<br/> For support requests, please contact us by going to our <a href="http://email.getpocket.com/wf/click?upn=S10v-2BfWRB4OIigzZ3tVxSzVtvnsL9TD3AibX-2F20JRgU-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt-2F1A1L7-2BfjpfZI6-2BRSl8rc2bxhHKWHNtT9kzkEy0cY5e18rdZ-2B9tZb0gspLSkL7Lo2kYNIKM3R0wY4-2FEBgnQI-2BK4imuk65F7484zy4E-2B0dWtunhFwvQ-2FkLIGT77DrQKHQ6BtRyWkqz6jWUBMWLb1gJzndywBGIsXr1S5icF3Gvb9tiwx4lGg82dTYw3tc1sJkyTfd-2BRfBDIK3ue2qXt1kSh6efcsXnR6UValKHh5gcx3vMlznNJJk97mA2zrWLuXi1exf13rnMC957xk6laXMh8YcOHgm8RFtapXW3mBc9-2B8uiGm7GAV1KXSwdhzIhiliI-2Fg6LnALUjtXvtMuHTfxYL70iXNYjEJDEjiNfoSGKGgmkeTlkexoPa6gbrlvTzmZ" style="color:#666666; text-decoration:underline;">support page</a>. </td> </tr> <tr class="original-only"> <td valign="top" height="22" style="font-size:2px;"> </td> </tr> <tr class="original-only"> <td valign="top" align="center"> <table width="275" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top" align="right"> <a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavVvGMXLmRUQyPiGcf9i1vP-2BNbnTDS4YteJHmstp2XC0tyoS9FFtF-2FJFsA-2BTewSIn5TLy7dru5f7PkYBO14UskpHU7PWd8qiSlGCuEgIZqxWTpKlW5WbehjdDG1A0S8W99wrmJVoyl2mzVyUQP2RyuFK-2BwZGLc9EbTSu1lFKO-2BuqveIl65tAxQuaQLwU3kAvTbw-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt-2F1A1L7-2BfjpfZI6-2BRSl8rc2bxhHKWHNtT9kzkEy0cY5e18rdZ-2B9tZb0gspLSkL7Lo2kYNIKM3R0wY4-2FEBgnQI-2BK4imuk65F7484zy4E-2B0dWtunhFwvQ-2FkLIGT77DrQKHQ6BtRyWkqz6jWUBMWLb1gJzndywBGIsXr1S5icF3Gvb9tiwx4lGg82dTYw3tc1sJksG4gjs-2Fs892TgHijHNfHQT3LMHtI90BGeVIzJ65Am1OWFE-2FUbufIqKs-2B-2FFzEZRhD5zVBUB342TWf8I0LbYObeOpVUHux3Gx-2BVsMp-2FjG8edlPTZXu9c-2Bkjuj5jFbHKAgHHb7-2Bh3-2ByPtvQUDaYLuO3Z92TzconO0SvB4yY-2FSuzTc3vX4pOQdWDjfLpQvLGg1wf" style="font-size:11px;font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;font-weight:bold;text-decoration:underline;"> Notification Settings </a> </td> <td valign="middle" align="center"> <img alt="" width="13" src="http://email-assets.getpocket.com/sep01-original.gif" /> </td> <td valign="top" align="left"> <a href="http://email.getpocket.com/wf/click?upn=Kih6kahtikEpOlxbCnUavbym7-2ByxEzk5R-2FyNUsaZglMddz-2BpXt-2By6jyn3dtrmRxWKVonHrdXar4iqDYX70FEuy4tkqJDIq7aJkC9sTBnl11BeRkE6VgkcuZ5loB4VV5StnZpHe1n5J54L8Um3EHpwf004msleTgWdwcWOn-2Bp47zoOhPcNP0IMJof-2FKFesfAAdEEb5NdGHq1g24EmjrVSIw-3D-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt-2F1A1L7-2BfjpfZI6-2BRSl8rc2bxhHKWHNtT9kzkEy0cY5e18rdZ-2B9tZb0gspLSkL7Lo2kYNIKM3R0wY4-2FEBgnQI-2BK4imuk65F7484zy4E-2B0dWtunhFwvQ-2FkLIGT77DrQKHQ6BtRyWkqz6jWUBMWLb1gJzndywBGIsXr1S5icF3Gvb9tiwx4lGg82dTYw3tc1sJkVOO-2F5EHKn-2BCQVWX4TbKyIpTIzJm4cLDYjFJ-2BeKHea6GVX2bN4LeX93B4ege6vRK1KGVbXiYGDejSWEmZ9CYE4QQfsbkHNm0q1Eay-2B17ZO6z6fpb5tbFq7viucD8r33YduIMPBoe6Ainjigq5Rb5mJS-2BaTTdt-2BhsdDX2HWz-2Fob9BqOjUY42RU95L1loxuTDtU" style="font-size:11px;font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;font-weight:bold;text-decoration:underline;"> Privacy Policy </a> </td> </tr> </table> </td> </tr> <tr> <td valign="top" height="32" style="font-size:2px;"> </td> </tr> <tr> <td valign="top" align="center"> <font style="font-size:10px; line-height:12px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> Read It Later, Inc., 731 Market Street Suite 410, San Francisco, CA 94108, USA </font> </td> </tr> <tr> <td valign="top" height="10" style="font-size:2px;"> </td> </tr> <tr> <td valign="top" align="center"> <font style="font-size:10px; line-height:12px; font-family:'HelveticaNeue','HelveticaNeueLTStd',Arial,Helvetica,sans-serif; color:#666666;"> © 2013 Read It Later, Inc. All Rights Reserved. </font> </td> </tr> <tr> <td valign="top" height="30" style="font-size:2px;"> </td> </tr> </table> </td> </tr> </table> <img src="http://email.getpocket.com/wf/open?upn=5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt-2F1A1L7-2BfjpfZI6-2BRSl8rc2bxhHKWHNtT9kzkEy0cY5e18rdZ-2B9tZb0gspLSkL7Lo2kYNIKM3R0wY4-2FEBgnQI-2BK4imuk65F7484zy4E-2B0dWtunhFwvQ-2FkLIGT77DrQKHQ6BtRyWkqz6jWUBMWLb1gJzndywBGIsXr1S5icF3Gvb9tiwx4lGg82dTYw3tc1sJkuXUAsKFPQCzrsNP-2Fd8hPeYFPg2Nn7CC7vIk487IqBJFOL3gk82c5tpt-2FL5sO5Y6YrtzX83SZJwzfmWOiFnImAqgTi-2Bs89v40CQCXYSg2Fq5dq5MvyjrIeKfjUh6OaCRE7qTJXy161d7hUhabjVP8w07jNPXztVhYbMHlhk4XoYp0cMBS2tMKG1Kxuo2KMsf8" alt="" width="1" height="1" border="0" style="height:1px !important;width:1px !important;border-width:0 !important;margin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;margin-left:0 !important;padding-top:0 !important;padding-bottom:0 !important;padding-right:0 !important;padding-left:0 !important;"/> TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-40706950686196355342013-09-19T19:24:00.001-04:002014-01-24T11:42:20.115-05:00Food for thought: Curing Cancer Isn't Really Worth All The Trouble<div>
Worth a quick read......</div>
<div>
<br /></div>
<div>
Per <strong>GOOGLE: Curing Cancer Isn't Really Worth All The Trouble</strong><br />
<a href="http://www.businessinsider.com/google-curing-cancer-isnt-really-worth-all-the-trouble-2013-9">http://www.businessinsider.com/google-curing-cancer-isnt-really-worth-all-the-trouble-2013-9</a></div>
<div>
<br />
<br />
<a href="http://2.bp.blogspot.com/-veg1isDxn_c/UjuHwKtkmjI/AAAAAAAAAE4/kma6bIDsQDo/s1600/FlipboardCover-786660.jpg"><img alt="" border="0" src="http://2.bp.blogspot.com/-veg1isDxn_c/UjuHwKtkmjI/AAAAAAAAAE4/kma6bIDsQDo/s320/FlipboardCover-786660.jpg" id="BLOGGER_PHOTO_ID_5925478996314987058" /></a></div>
TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-58429404553842946232013-06-04T14:21:00.001-04:002014-01-24T11:43:09.931-05:00The Logic Of Biologics - Is Regeneron The Next Roche?<!-- outer container --> <br />
<table bgcolor="#efefef" border="0" cellpadding="0" cellspacing="0" style="background: #efefef; font-family: Helvetica,Arial,sans-serif; table-layout: fixed; width: 100%px;"> <tbody>
<tr> <td class="top_spacer" height="10" style="font-size: 1px;"></td> </tr>
<tr> <td valign="top"><!-- tile --> <br />
<table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" class="tile" style="border-bottom: 2px solid #cdcdcd; border: 1px solid #cdcdcd; max-width: 600px; min-width: 300px; width: 80%px;"> <!-- IF rainbow bar --> <!-- ENDIF rainbow bar --> <!-- IF attribution --> <tbody>
<tr> <td><table bgcolor="#f8f8f8" border="0" cellpadding="0" cellspacing="0" class="attribution" style="color: #777777; font-size: 18px; width: 100%px;"> <tbody>
<tr> <td class="attribution_top_spacer" colspan="3" height="21" style="font-size: 1px; line-height: 1px;"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td><table bgcolor="#f8f8f8" border="0" cellpadding="0" cellspacing="0" style="color: #777777; font-size: 18px; width: 100%px;"> <tbody>
<tr> <!-- If no avatar do not include profile_image td and set the second div to have a colspan="2" --> <td class="profile_image" height="40" valign="middle" width="53"><img border="0" src="http://s3.amazonaws.com/pocket-profile-images/b75adba84005d725f236a3f3e27090eb5d6456f.jpg" height="40" style="-moz-border-radius: 20px; -ms-border-radius: 20px; -webkit-border-radius: 20px; border-radius: 20px;" width="40" /></td> <td valign="middle"><b style="color: #555555;">Tim Gallagher</b> shared<span class="with_you"> with you</span>: </td> </tr>
</tbody></table>
</td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="space_vertical" colspan="3" height="13" style="font-size: 1px; line-height: 1px;"></td> </tr>
<!-- IF comment -->
<tr> <td class="side_spacer" width="25"></td> <td class="comment" style="line-height: 22px;">Interesting stats from this article showing the value of Biologics >small molecules "For preclinical compounds, it takes an average of 44 small-molecule candidates to achieve one final approval versus nine biologic drug candidates In Phase II development, it takes an average of 11 small-molecule candidates to achieve one final approval versus four biologic drug candidates Only 19 percent of small-molecule compounds will advance from Phase II to Phase III studies, versus 44 percent for biologics Only 60 percent of small-molecule compounds will successfully complete Phase III studies versus 79 percent for biologics" </td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="space_vertical" colspan="3" height="20" style="font-size: 1px; line-height: 1px;"></td> </tr>
<!-- ENDIF comment -->
<tr> <td bgcolor="white" class="caret" colspan="3" height="24" style="background: white url(http://email-assets.getpocket.com/caretShadow.gif) left top no-repeat;"><!-- caret / bottom edge --> </td> </tr>
</tbody></table>
</td> </tr>
<!-- END IF attribution --> <!-- IF item -->
<tr> <td><table border="0" cellpadding="0" cellspacing="0" style="width: 100%px;"> <tbody>
<tr> <td class="space_above_title" colspan="3" height="26"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td><a class="title" href="http://email.getpocket.com/wf/click?upn=taBGH0n3p5fmoPVsUKbIp9xO-2BcfO2jFo6riOqMkLkTSxYyYgvHSOUAvRSL76navJyTppyhNCd6qj06KL575sidaYk1WdgJsveta-2BSDtSbVBVwsCpjM6gQBlqD2PauaaFuKacun500ATkbfxvHIB5CzEPtV2FKt-2Fngnn8vAoasSY5bxGWbKpxYRhwYk-2FO-2FS7V_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZto5M9Jd0uHksMHGKFhJUkjYFBhxUdMvX34VI1FB8-2FwqRBk3X45-2F-2FSHBwk1yTcoYxY0EQhz2cV2i8gKVvs5D7utQJ7QDjl6ycFIKHc-2BzQQr6abBHLl10-2B5GiSIM7Iwv-2F1bPLvg877xck0LTrkmu09iydPlrvcr4UGY4MyFKVCzSXIvete-2Byuqt6SUgaBLG1du3MrvglaHOx49EgCUW4un-2FEw69S6c2oOsCNMaqpguLjyaDVjNEpXFt8f0dDfZAKwN-2F61aTxneWvCu2qXG1DMXipzFCuP012zIRwwQTBkLBiJVYQS-2FCpftApDBJw2-2BlC4klAS3ez8HWso-2Fx2Udc3kiREQ-3D-3D" style="color: #3abcb6; font-size: 22px; font-weight: bold;">The Logic Of Biologics - Is Regeneron The Next Roche?</a> </td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="domain_spacer" colspan="3" height="7" style="font-size: 1px; line-height: 1px;"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td class="domain"><a href="http://email.getpocket.com/wf/click?upn=lTYCVE-2FXSkcjFMk6-2BsrUOrUzIQxIyt-2FXTocT3j8r6bM-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZto5M9Jd0uHksMHGKFhJUkjYFBhxUdMvX34VI1FB8-2FwqRBk3X45-2F-2FSHBwk1yTcoYxY0EQhz2cV2i8gKVvs5D7utQJ7QDjl6ycFIKHc-2BzQQr6abBHLl10-2B5GiSIM7Iwv-2F1bPLvg877xck0LTrkmu09iydPlrvcr4UGY4MyFKVCzSXIvete-2Byuqt6SUgaBLG1du3IIOxGdXkHbhjFnAiWQgUZWrdTkqztcXPaK6IY0nAXPx-2FLH4pv7wS9NeecVZvH-2FGJ5G5vVHgFAg-2BTzsSxTEM0S9io8g-2Bl6aVyMgOrUWW-2BexdtFndP-2F34XopVvKOQe3uCwnZn0Rnio4xPMQftE5gqSAQ-3D-3D" style="color: #999999; font-size: 16px; text-decoration: none;">forbes.com</a></td> <td class="side_spacer" width="25"></td> </tr>
<!-- IF quote -->
<tr> <td class="side_spacer" width="25"></td> <td class="space_vertical" colspan="3" height="32"></td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td><table border="0" cellpadding="0" cellspacing="0" style="width: 100%px;"> <tbody>
<tr> <td class="quote_spacer" style="border-left: 3px solid #CCCCCC; font-size: 1px;" width="30"></td> <td class="quote" style="color: #777777; font-size: 18px; font-style: italic; line-height: 21px;">For preclinical compounds, it takes an average of 44 small-molecule candidates to achieve one final approval versus nine biologic drug candidates In Phase II development, it takes an average of 11 small-molecule candidates to achieve one final approval versus four biologic drug candidates Only 19 percent of small-molecule compounds will advance from Phase II to Phase III studies, versus 44 percent for biologics Only 60 percent of small-molecule compounds will successfully complete Phase III studies versus 79 percent for biologics </td> </tr>
</tbody></table>
</td> <td class="side_spacer" width="25"></td> </tr>
<!-- ENDIF quote -->
<tr> <td class="side_spacer" width="25"></td> <td class="space_above_buttons" colspan="3" height="36"></td> <td class="side_spacer" width="25"></td> </tr>
</tbody></table>
</td> </tr>
<!-- ENDIF item --> <!-- IF buttons --> <!-- ENDIF buttons --> </tbody></table>
</td> </tr>
</tbody></table>
<br /><br /><img alt="" border="0" src="http://email.getpocket.com/wf/open?upn=5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZto5M9Jd0uHksMHGKFhJUkjYFBhxUdMvX34VI1FB8-2FwqRBk3X45-2F-2FSHBwk1yTcoYxY0EQhz2cV2i8gKVvs5D7utQJ7QDjl6ycFIKHc-2BzQQr6abBHLl10-2B5GiSIM7Iwv-2F1bPLvg877xck0LTrkmu09iydPlrvcr4UGY4MyFKVCzSXLsMt39rbYenczewxVPPS9zKqcN5bsVWtAkZR3dXgKs-2B9DElj00LgKOWyJmxRKCAX-2Fl-2BqBgTwu6vksttAFrypnEfQ3BBIu0jWlmq6439gq3dUKRepGlyBCocbiNOMFZKQknWP7GXMucjFp1QxYgqpIbWKqcUSxdBcbKbMykxyXHVQ-3D-3D" height="1" style="border-width: 0 !important; height: 1px !important; margin-bottom: 0 !important; margin-left: 0 !important; margin-right: 0 !important; margin-top: 0 !important; padding-bottom: 0 !important; padding-left: 0 !important; padding-right: 0 !important; padding-top: 0 !important; width: 1px !important;" width="1" /> TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-90922253675159288582013-05-03T11:14:00.001-04:002014-01-24T11:44:03.125-05:00Unhealthy Prognosis for Venture-Backed Diagnostics<!-- outer container --> <br />
<table bgcolor="#efefef" border="0" cellpadding="0" cellspacing="0" style="background: #efefef; font-family: Helvetica,Arial,sans-serif; table-layout: fixed; width: 100%px;"> <tbody>
<tr> <td class="top_spacer" height="10" style="font-size: 1px;"></td> </tr>
<tr> <td valign="top"><!-- tile --> <br />
<table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" class="tile" style="border-bottom: 2px solid #cdcdcd; border: 1px solid #cdcdcd; max-width: 600px; min-width: 300px; width: 80%px;"> <!-- IF rainbow bar --> <!-- ENDIF rainbow bar --> <!-- IF attribution --> <tbody>
<tr> <td><table bgcolor="#f8f8f8" border="0" cellpadding="0" cellspacing="0" class="attribution" style="color: #777777; font-size: 18px; width: 100%px;"> <tbody>
<tr> <td class="attribution_top_spacer" colspan="3" height="21" style="font-size: 1px; line-height: 1px;"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td><table bgcolor="#f8f8f8" border="0" cellpadding="0" cellspacing="0" style="color: #777777; font-size: 18px; width: 100%px;"> <tbody>
<tr> <!-- If no avatar do not include profile_image td and set the second div to have a colspan="2" --> <td class="profile_image" height="40" valign="middle" width="53"><img border="0" src="http://s3.amazonaws.com/pocket-profile-images/b75adba84005d725f236a3f3e27090eb5d6456f.jpg" height="40" style="-moz-border-radius: 20px; -ms-border-radius: 20px; -webkit-border-radius: 20px; border-radius: 20px;" width="40" /></td> <td valign="middle"><b style="color: #555555;">Tim Gallagher</b> shared<span class="with_you"> with you</span>: </td> </tr>
</tbody></table>
</td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="space_vertical" colspan="3" height="13" style="font-size: 1px; line-height: 1px;"></td> </tr>
<!-- IF comment -->
<tr> <td class="side_spacer" width="25"></td> <td class="comment" style="line-height: 22px;">Some brilliant caution on molecular diagnostics from Bruce Booth. Turns out, MDx development is just about as risky and capital intensive as therapeutic development, with arguably less upside and liquidity. </td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="space_vertical" colspan="3" height="20" style="font-size: 1px; line-height: 1px;"></td> </tr>
<!-- ENDIF comment -->
<tr> <td bgcolor="white" class="caret" colspan="3" height="24" style="background: white url(http://email-assets.getpocket.com/caretShadow.gif) left top no-repeat;"><!-- caret / bottom edge --> </td> </tr>
</tbody></table>
</td> </tr>
<!-- END IF attribution --> <!-- IF item -->
<tr> <td><table border="0" cellpadding="0" cellspacing="0" style="width: 100%px;"> <tbody>
<tr> <td class="space_above_title" colspan="3" height="26"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td><a class="title" href="http://email.getpocket.com/wf/click?upn=taBGH0n3p5fmoPVsUKbIp2MRKQAmwdoSwl3MI4GQBJo5FGqM-2FO5sBdxuYDVOpGKRa7iVfPAK35UNK2k6A0TmJV1PjZtSi9U6gVF7nc5zJbx2KOJiPrBsTaTqwDCVniGf7Ym3QMjY3mzEx8wKqC-2BkVohd2ZAXUb-2FgxMwlU4dw2y-2FTGVzpAnNSFhtzOkHbe40P_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt8X0nlZW6PGLlMQV-2BfSEH4JOR1VPfLuzXgicf3Tzrv3RECl4MDoVYhbQqQz9sPAYy-2FL-2FBX-2B2FBpWMd4Z91fWyR5xrHQ7tOh-2BXckcuiJxNxOBqgAk-2Bjo1-2FRREge3z9HlF6GuPSmYvnLAWzR7qQ8d2vIdIyRe0HoOENvaVfAQUmx9ZnA1JAWE6OlNadiCT70T8P7BKl3-2Bts5gvxfPjf04QTfCaXfMso-2Fpt4heSMTODQ46qpRBcm9ix0i0AmuKZ0eeDOulOeyxxFQMJzTo-2Bg-2FcXHHbldcK5eQx-2BXvamGbGGu-2BExvA9EuM-2BVKgtyTWNTw9w0c" style="color: #3abcb6; font-size: 22px; font-weight: bold;">Unhealthy Prognosis for Venture-Backed Diagnostics</a> </td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="domain_spacer" colspan="3" height="7" style="font-size: 1px; line-height: 1px;"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td class="domain"><a href="http://email.getpocket.com/wf/click?upn=lTYCVE-2FXSkcjFMk6-2BsrUOrUzIQxIyt-2FXTocT3j8r6bM-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt8X0nlZW6PGLlMQV-2BfSEH4JOR1VPfLuzXgicf3Tzrv3RECl4MDoVYhbQqQz9sPAYy-2FL-2FBX-2B2FBpWMd4Z91fWyR5xrHQ7tOh-2BXckcuiJxNxOBqgAk-2Bjo1-2FRREge3z9HlF6GuPSmYvnLAWzR7qQ8d2vIdIyRe0HoOENvaVfAQUmx9bDOcXV-2Bbnv9ncTUdKgpB6e7CuBfVIQzwEE10-2FxK67Q32YlNK4Ga2gyiIGEHW4rbqFeiXBQ8kd7Uq-2Fy-2FLQ4xwwRWLJNgbaECf3WUFuUUT0u8wdNaJoejrYRa-2Bci3aaoOj-2FOL3ypdzUO9x4wH3XvhxLl" style="color: #999999; font-size: 16px; text-decoration: none;">forbes.com</a></td> <td class="side_spacer" width="25"></td> </tr>
<!-- IF quote --> <!-- ENDIF quote -->
<tr> <td class="side_spacer" width="25"></td> <td class="space_above_buttons" colspan="3" height="36"></td> <td class="side_spacer" width="25"></td> </tr>
</tbody></table>
</td> </tr>
<!-- ENDIF item --> <!-- IF buttons --> <!-- ENDIF buttons --> </tbody></table>
</td> </tr>
</tbody></table>
<br />
<br />
<img alt="" border="0" src="http://email.getpocket.com/wf/open?upn=5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt8X0nlZW6PGLlMQV-2BfSEH4JOR1VPfLuzXgicf3Tzrv3RECl4MDoVYhbQqQz9sPAYy-2FL-2FBX-2B2FBpWMd4Z91fWyR5xrHQ7tOh-2BXckcuiJxNxOBqgAk-2Bjo1-2FRREge3z9HlF6GuPSmYvnLAWzR7qQ8d2vIdIyRe0HoOENvaVfAQUmx9Zd5qCSAU-2FSj3bVplCevWsT1Vu0zvGeYnFKVqfrlBeojZPQnLFGRhaNb8-2BgIMrxQ5sh-2BjuD0cVn6jNA-2Fr0cY2A8CgKF3iYPzVO5YHt4W9YJFg6UzejSXloNf4Gs7FHj-2BSyi6Xd2r1ae-2BZr9j8IufPWd" height="1" style="border-width: 0 !important; height: 1px !important; margin-bottom: 0 !important; margin-left: 0 !important; margin-right: 0 !important; margin-top: 0 !important; padding-bottom: 0 !important; padding-left: 0 !important; padding-right: 0 !important; padding-top: 0 !important; width: 1px !important;" width="1" /> TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-16385672609877166932013-04-26T10:46:00.001-04:002014-01-24T11:44:48.669-05:00Merck Could Return To Greatness If CEO Can Leave His Own Past Behind<!-- outer container --> <br />
<table bgcolor="#efefef" border="0" cellpadding="0" cellspacing="0" style="background: #efefef; font-family: Helvetica,Arial,sans-serif; table-layout: fixed; width: 100%px;"> <tbody>
<tr> <td class="top_spacer" height="10" style="font-size: 1px;"></td> </tr>
<tr> <td valign="top"><!-- tile --> <br />
<table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" class="tile" style="border-bottom: 2px solid #cdcdcd; border: 1px solid #cdcdcd; max-width: 600px; min-width: 300px; width: 80%px;"> <!-- IF rainbow bar --> <!-- ENDIF rainbow bar --> <!-- IF attribution --> <tbody>
<tr> <td><table bgcolor="#f8f8f8" border="0" cellpadding="0" cellspacing="0" class="attribution" style="color: #777777; font-size: 18px; width: 100%px;"> <tbody>
<tr> <td class="attribution_top_spacer" colspan="3" height="21" style="font-size: 1px; line-height: 1px;"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td><table bgcolor="#f8f8f8" border="0" cellpadding="0" cellspacing="0" style="color: #777777; font-size: 18px; width: 100%px;"> <tbody>
<tr> <!-- If no avatar do not include profile_image td and set the second div to have a colspan="2" --> <td class="profile_image" height="40" valign="middle" width="53"><img border="0" src="http://s3.amazonaws.com/pocket-profile-images/b75adba84005d725f236a3f3e27090eb5d6456f.jpg" height="40" style="-moz-border-radius: 20px; -ms-border-radius: 20px; -webkit-border-radius: 20px; border-radius: 20px;" width="40" /></td> <td valign="middle"><b style="color: #555555;">Tim Gallagher</b> shared<span class="with_you"> with you</span>: </td> </tr>
</tbody></table>
</td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="space_vertical" colspan="3" height="13" style="font-size: 1px; line-height: 1px;"></td> </tr>
<!-- IF comment -->
<tr> <td class="side_spacer" width="25"></td> <td class="comment" style="line-height: 22px;">Reading this profile of Merck CEO Leslie Frazier made me think that someone had found a 2004 article about Pfizer and Jeff Kindler and had just done a search and replace with Merck and Frazier in place of Pfizer and Kindler. Wallowing big Pharma company hires former general counsel as CEO, emphasizes R&D productivity, but does a mega-merger. Big pharma top jobs demand serious people management skills and vision. Without exception, lawyers are not visionary, transformative leaders. I just can't see this turning out well. </td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="space_vertical" colspan="3" height="20" style="font-size: 1px; line-height: 1px;"></td> </tr>
<!-- ENDIF comment -->
<tr> <td bgcolor="white" class="caret" colspan="3" height="24" style="background: white url(http://email-assets.getpocket.com/caretShadow.gif) left top no-repeat;"><!-- caret / bottom edge --> </td> </tr>
</tbody></table>
</td> </tr>
<!-- END IF attribution --> <!-- IF item -->
<tr> <td><table border="0" cellpadding="0" cellspacing="0" style="width: 100%px;"> <tbody>
<tr> <td class="space_above_title" colspan="3" height="26"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td><a class="title" href="http://email.getpocket.com/wf/click?upn=taBGH0n3p5fmoPVsUKbIpwiIU7bX4FzMrv-2F-2BLEqSsgswN1LYSPLN2N2OhwSUUFqr6NnGQRC9vOT-2BgAT4Eoo-2F7sV8-2F-2BDYHvUymAku80SCl6Y5agOQdSGdbyZlLYmxaZYOogkiBIiX9ahS2Gft13-2BlcHNBR5ggN2a-2F7Vu8bET0WuxRO5mV8ZE680ejyIOkZopL_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt59MUIZr56xydA-2BLtWF3SSwMLAZ3Qe-2FX1g1f7vLCFIj0yEWFrmkmDWl9248ROXIa-2FkGh-2Bbs2vwsjjOA-2Fluf5B7HEvbEs5Uu27dR8alVPyeQCI3KW6Wj9Ax4Ai9jo0uL-2FH602oCVPP3eTEAX88fNENwtuN4KW3FUUyo-2FzzCfPx-2FzTopo-2Fagij4oPA67dbWF0fWlHAP2wVY-2B4feNlTHRgK3L5QlAQri72DvhIo2jX8aWjBF1BU3WsyhnoFMNWRPEtYTcamUdmkcZTDrjC53o4cRBxZYV7xYrLlGusLOlxR59XOGnDwNtSV0CvNZ6F4HDOcl" style="color: #3abcb6; font-size: 22px; font-weight: bold;">Merck Could Return To Greatness If CEO Can Leave His Own Past Behind</a> </td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="domain_spacer" colspan="3" height="7" style="font-size: 1px; line-height: 1px;"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td class="domain"><a href="http://email.getpocket.com/wf/click?upn=lTYCVE-2FXSkcjFMk6-2BsrUOrUzIQxIyt-2FXTocT3j8r6bM-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt59MUIZr56xydA-2BLtWF3SSwMLAZ3Qe-2FX1g1f7vLCFIj0yEWFrmkmDWl9248ROXIa-2FkGh-2Bbs2vwsjjOA-2Fluf5B7HEvbEs5Uu27dR8alVPyeQCI3KW6Wj9Ax4Ai9jo0uL-2FH602oCVPP3eTEAX88fNENwtuN4KW3FUUyo-2FzzCfPx-2FzQlh4kU3wzG6BiEOvPT1goNY2d94u2mYtWNtrXelF7VTjyNOZU9o9XRew020cs-2F6VSNG12vkdXlT-2FNapjFqq97qsxpCHHRps4OsKjf6J7w9i-2F26aJNPlyKOnUO83fqM0eJ6RBJSwtb-2FrCtiPC0jy4mw" style="color: #999999; font-size: 16px; text-decoration: none;">forbes.com</a></td> <td class="side_spacer" width="25"></td> </tr>
<!-- IF quote --> <!-- ENDIF quote -->
<tr> <td class="side_spacer" width="25"></td> <td class="space_above_buttons" colspan="3" height="36"></td> <td class="side_spacer" width="25"></td> </tr>
</tbody></table>
</td> </tr>
<!-- ENDIF item --> <!-- IF buttons --> <!-- ENDIF buttons --> </tbody></table>
<img alt="" border="0" src="http://email.getpocket.com/wf/open?upn=5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZt59MUIZr56xydA-2BLtWF3SSwMLAZ3Qe-2FX1g1f7vLCFIj0yEWFrmkmDWl9248ROXIa-2FkGh-2Bbs2vwsjjOA-2Fluf5B7HEvbEs5Uu27dR8alVPyeQCI3KW6Wj9Ax4Ai9jo0uL-2FH602oCVPP3eTEAX88fNENwtuN4KW3FUUyo-2FzzCfPx-2FzTIfN53QvlUgJfhiUFgysDGSkvkGutCUzKEfrKTfxV3P-2FnBznMjOnAUBoZXcAJteZJues9VoSreO0eLCogWvbfdhc0rgM95p9O-2BQsORJ2YKbpAat4XBQf8-2BpfiOUguESOVIbpPidP9-2B55lNFkQaMaAbBKnlJSCKdfilyVq6SRJDjA-3D-3D" height="1" style="background-color: transparent; border-width: 0px !important; height: 1px !important; margin: 0px !important; padding: 0px !important; width: 1px !important;" width="1" /></td></tr>
</tbody></table>
TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-44964463320853728462013-04-23T23:10:00.001-04:002014-01-24T11:45:31.125-05:00A Biotech Innovation Supply Chain: Reality or Fantasy?<!-- outer container --> <br />
<table bgcolor="#efefef" border="0" cellpadding="0" cellspacing="0" style="background: #efefef; font-family: Helvetica,Arial,sans-serif; table-layout: fixed; width: 100%px;"> <tbody>
<tr> <td class="top_spacer" height="10" style="font-size: 1px;"></td> </tr>
<tr> <td valign="top"><!-- tile --> <br />
<table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" class="tile" style="border-bottom: 2px solid #cdcdcd; border: 1px solid #cdcdcd; max-width: 600px; min-width: 300px; width: 80%px;"> <!-- IF rainbow bar --> <!-- ENDIF rainbow bar --> <!-- IF attribution --> <tbody>
<tr> <td><table bgcolor="#f8f8f8" border="0" cellpadding="0" cellspacing="0" class="attribution" style="color: #777777; font-size: 18px; width: 100%px;"> <tbody>
<tr> <td class="attribution_top_spacer" colspan="3" height="21" style="font-size: 1px; line-height: 1px;"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td><table bgcolor="#f8f8f8" border="0" cellpadding="0" cellspacing="0" style="color: #777777; font-size: 18px; width: 100%px;"> <tbody>
<tr> <!-- If no avatar do not include profile_image td and set the second div to have a colspan="2" --> <td class="profile_image" height="40" valign="middle" width="53"><img border="0" src="http://s3.amazonaws.com/pocket-profile-images/b75adba84005d725f236a3f3e27090eb5d6456f.jpg" height="40" style="-moz-border-radius: 20px; -ms-border-radius: 20px; -webkit-border-radius: 20px; border-radius: 20px;" width="40" /></td> <td valign="middle"><b style="color: #555555;">Tim Gallagher</b> shared<span class="with_you"> with you</span>: </td> </tr>
</tbody></table>
</td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="space_vertical" colspan="3" height="13" style="font-size: 1px; line-height: 1px;"></td> </tr>
<!-- IF comment -->
<tr> <td class="side_spacer" width="25"></td> <td class="comment" style="line-height: 22px;">Love this idea, but am concerned about the practical hurdles. Will Pharma by less than best of breed? Will VC take less than top dollar? </td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="space_vertical" colspan="3" height="20" style="font-size: 1px; line-height: 1px;"></td> </tr>
<!-- ENDIF comment -->
<tr> <td bgcolor="white" class="caret" colspan="3" height="24" style="background: white url(http://email-assets.getpocket.com/caretShadow.gif) left top no-repeat;"><!-- caret / bottom edge --> </td> </tr>
</tbody></table>
</td> </tr>
<!-- END IF attribution --> <!-- IF item -->
<tr> <td><table border="0" cellpadding="0" cellspacing="0" style="width: 100%px;"> <tbody>
<tr> <td class="space_above_title" colspan="3" height="26"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td><a class="title" href="http://email.getpocket.com/wf/click?upn=taBGH0n3p5fmoPVsUKbIpyv55kOGKD24nfY-2Ftzrvk8r9VIPsVDHWK0xXx3R5-2BsZG8habmU9griaiXYHSXpYl4pcnlDXTeSw3DB-2B3wl6fxO0tppdoolLRFaogmlo-2BnX5uUxAlnpLxNAbsABqWniM7vH2b3v3whRn1YtKDT5rxkfDsE9fRcTuJvDWoceuY7Hhl_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtCeDZuQuBld1TDjkq1jYi-2FxnOoYjNc9GB-2Fuu2-2FGNGMH6Lz7mwWHDTGAgbtfX-2F9srIBc73rWC-2B1eTvS3v-2F9SyD3B4HRvuVylm-2Bc3y-2BP8tTIYgH7qAF-2F4y-2Fg1k28exHlvBaqsZ8MTjar1N3JsleL-2Fjpi4e-2FxksAH7CEWaOv-2F9GsyxqGNJnrp5wUHDbGJQWJOWOoAK-2FGr3HuQ7fMwJ0wuNgUkKpIOR8tW3Kf38zcqyIKuIuPOkopaMMOC8ljxdb3pprnLjFh-2Bn5Zg-2BmtgoeOSAUn6VHuM1-2FyLIRFtIJpBvDhhg2B7j-2FDKigkAbpTEB6X-2BtQ9" style="color: #3abcb6; font-size: 22px; font-weight: bold;">A Biotech Innovation Supply Chain: Reality or Fantasy?</a> </td> <td class="side_spacer" width="25"></td> </tr>
<tr> <td class="domain_spacer" colspan="3" height="7" style="font-size: 1px; line-height: 1px;"></td> </tr>
<tr> <td class="side_spacer" width="25"></td> <td class="domain"><a href="http://email.getpocket.com/wf/click?upn=mdBKml5jOijqk-2BNftnw9x9QTJ-2BIrzoyTccJb90i8XzU-3D_5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtCeDZuQuBld1TDjkq1jYi-2FxnOoYjNc9GB-2Fuu2-2FGNGMH6Lz7mwWHDTGAgbtfX-2F9srIBc73rWC-2B1eTvS3v-2F9SyD3B4HRvuVylm-2Bc3y-2BP8tTIYgH7qAF-2F4y-2Fg1k28exHlvBaqsZ8MTjar1N3JsleL-2Fjpi4e-2FxksAH7CEWaOv-2F9Gsyxot7qz0sXBFRzrHHSFhNvaMot6lWd5PWnVNYrDKTz9SwyhMGcuwme1t5VMOQwEQ8hNRlQq7gItS8Rl-2B0Imvge9zQxTMb8zFrUjOARQLWeTAw6Hw3VqwRtL1Ut2z6Ac7rhgVvvJn8Mb7avnQFgjUFlAt" style="color: #999999; font-size: 16px; text-decoration: none;">xconomy.com</a></td> <td class="side_spacer" width="25"></td> </tr>
<!-- IF quote --> <!-- ENDIF quote -->
<tr> <td class="side_spacer" width="25"></td> <td class="space_above_buttons" colspan="3" height="36"></td> <td class="side_spacer" width="25"></td> </tr>
</tbody></table>
</td> </tr>
<!-- ENDIF item --> <!-- IF buttons --> <!-- ENDIF buttons --> </tbody></table>
</td> </tr>
</tbody></table>
<br /><img alt="" border="0" src="http://email.getpocket.com/wf/open?upn=5wLCd9Y4oeTTOqyIGGr1t2Y0xpYX873WBC2DN2nvZJ7umsyK-2BFJ628QgomZabp89CvqCtQbg2SSqY5ySWDcwUtz1E0LlwkRHAZnVYp7DmR0sd8cCCwffz51TU4fuepxCA0I0zB8tQUfcoAD01OGkiskBKawBi5coXp1cir9ckkQuXPuG-2B3T83545ATs2mJZtCeDZuQuBld1TDjkq1jYi-2FxnOoYjNc9GB-2Fuu2-2FGNGMH6Lz7mwWHDTGAgbtfX-2F9srIBc73rWC-2B1eTvS3v-2F9SyD3B4HRvuVylm-2Bc3y-2BP8tTIYgH7qAF-2F4y-2Fg1k28exHlvBaqsZ8MTjar1N3JsleL-2Fjpi4e-2FxksAH7CEWaOv-2F9Gsyxq8mO-2B13ajF0qHOV-2FHloekHX3jPtoDgtrQAZ6ODNxLteWA6qw2v7uERCSgdjikxA8QJJrFXCjLjPfQEHlQ09UEaNjzmRPCCOhnZpzLXB5-2Bj6oSi4hfWdAVo56LQXuDKYvnCrbL-2BxAlOItI-2F3UFixsS0nyZWhbqdC3l5uuldA5sS7Q-3D-3D" height="1" style="border-width: 0px !important; height: 1px !important; margin: 0px !important; padding: 0px !important; width: 1px !important;" width="1" />TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-62280553110696308772013-04-18T09:25:00.000-04:002013-04-18T14:51:04.673-04:00Have We Wasted 7 Years and $100 Million Dollars on GWAS Studies?<div>Pretty much......</div><div><br></div><div><a href="http://gabeinformatics.posterous.com/139178992">http://gabeinformatics.posterous.com/139178992</a><br><br>Sent from Pocket - <a href="http://readitlater.com/go?src=email">Get it free!</a></div>TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com1tag:blogger.com,1999:blog-8770049802106489152.post-90639444779407832972013-04-06T13:58:00.001-04:002013-04-06T13:58:58.307-04:00Drug patents: A fool’s game | The Economist<span class="Apple-Mail-URLShareWrapperClass" contenteditable="false"><span class="Apple-Mail-URLShareUserContentTopClass" style="line-height: 14px !important; text-align: left !important; font-size: 14px; " applecontenteditable="true"><font color="#11053b" face="Helvetica Neue">I was reading the article below regarding Novartis' loss in the battle to patent protect Gleevec in India, which is news in an of itself, but an amazing stat jumped out at me in the article that warrants amplification:</font></span></span><div><span class="Apple-Mail-URLShareWrapperClass" contenteditable="false"><span class="Apple-Mail-URLShareUserContentTopClass" style="line-height: 14px !important; text-align: left !important; font-size: 14px; " applecontenteditable="true"><font color="#11053b" face="Helvetica Neue"><br></font></span></span></div><div><span class="Apple-Mail-URLShareWrapperClass" contenteditable="false"><span class="Apple-Mail-URLShareUserContentTopClass" style="line-height: 14px !important; text-align: left !important; font-size: 14px; " applecontenteditable="true"><i><font color="#11053b" face="Helvetica Neue"><a href="http://www.pwc.com/jp/ja/japan-knowledge/archive/assets/pdf/pharma-2020-vision-to-decision.pdf" style="margin: 0px; padding: 0px; border: 0px; vertical-align: baseline; text-decoration: none; line-height: 23px; text-align: -webkit-auto; ">PwC</a><span style="line-height: 23px; text-align: -webkit-auto; ">, a consultancy, expects Indian drug sales to grow from $16 billion in 2011 to $49 billion by 2020.</span></font></i></span></span></div><div><span class="Apple-Mail-URLShareWrapperClass" contenteditable="false"><span class="Apple-Mail-URLShareUserContentTopClass" style="line-height: 14px !important; text-align: left !important; font-size: 14px; " applecontenteditable="true"><i><font color="#11053b" face="Helvetica Neue"><span style="line-height: 23px; text-align: -webkit-auto; "><br></span></font></i></span></span></div><div><div style="text-align: -webkit-auto;"><font color="#11053b" face="Helvetica Neue"><span style="line-height: 23px; font-size: 14px;">First of all, Holy Crap, that's some big growth. What an opportunity for an industry. (But think about how much growth remains beyond PWC's 2020 figure: consider that the </span><a href="http://wiki.answers.com/Q/What_is_the_current_global_pharmaceutical_market_size">total US pharmaceutical market was $200B in 2006.</a><span style="line-height: 23px; font-size: 14px;">)</span></font></div><div style="text-align: -webkit-auto;"><font color="#11053b" face="Helvetica Neue"><span style="line-height: 23px; font-size: 14px;"><br></span></font></div><div style="text-align: -webkit-auto;"><font color="#11053b" face="Helvetica Neue"><span style="line-height: 23px; font-size: 14px;">But more importantly, consider the ramifications for India. It will be very interesting to see life expectancies rise as pharma spending triples. (And through improvements in all other areas (delivery, access, etc.)</span></font></div><div style="text-align: -webkit-auto;"><font color="#11053b" face="Helvetica Neue"><span style="line-height: 23px; font-size: 14px;"><br></span></font></div><div style="text-align: -webkit-auto;"><font color="#11053b" face="Helvetica Neue"><span style="line-height: 23px; font-size: 14px;">PWC seems to expect the majority of growth to come from generics, which takes away from the opportunity for big Pharma, but taking a wider industry view, this is very exciting.</span></font></div><div style="text-align: -webkit-auto;"><br></div><div style="text-align: -webkit-auto;"><br></div><div style="text-align: -webkit-auto;"><font color="#11053b" face="Helvetica Neue"><span style="font-size: 14px; line-height: 23px;">(bonus: the article also labels Gleevec a $4B product. That's a long way from Novartis' initial expectations of ~$200M in annual revenue.)</span></font></div><div style="text-align: -webkit-auto;"><font color="#4a4a4a" face="Arial, sans-serif"><span style="font-size: 15px; line-height: 23px;"><br></span></font></div><span class="Apple-Mail-URLShareWrapperClass" contenteditable="false"><span class="Apple-Mail-URLShareSharedContentClass" style="position: relative !important; " applecontenteditable="true"><base href="http://www.economist.com/blogs/schumpeter/2013/04/drug-patents"><div><div class="original-url"><a href="http://www.economist.com/blogs/schumpeter/2013/04/drug-patents">http://www.economist.com/blogs/schumpeter/2013/04/drug-patents</a><br><br></div><div id="article" onscroll="articleScrolled();" class="auto-hyphenated" style="-webkit-locale: en; "> <!-- This node will contain a number of 'page' class divs. --> <div class="page" style="font-family: Palatino, Georgia, Times, 'Times New Roman', serif; font-size: 14px; line-height: 1.4; "><h1 class="title">A fool's game</h1> <div class="float right" style="width: 590px; "> <img src="http://media.economist.com/sites/default/files/imagecache/original-size/images/2013/04/blogs/schumpeter/india590.jpg" alt="" title="" width="590" height="333" style="float: none; "> </div><p>NOVARTIS spent nearly 15 years seeking a patent in India for Glivec, a medicine for chronic myeloid leukemia. That quest reached its dead end, at last, on April 1st. India's <a href="http://supremecourtofindia.nic.in/outtoday/patent.pdf">Supreme Court</a> rejected the Swiss drugmaker's patent application. Glivec (marketed in America as "Gleevec") is a blockbuster, earning the Swiss drugmaker <a href="http://www.novartis.com/downloads/investors/reports/novartis-annual-report-2012-en.pdf">$4.7 billion</a> last year. Its prospects in India are now zilch.</p><p>The case was watched closely by virtually everyone with an interest in selling medicines or benefiting from them, including drug firms, trade officials and patient advocates. Drug companies, facing paltry growth in rich countries, want to sell medicines to developing ones where demand for new drugs is rising along with rates of chronic disease. But governments are keen to boost their own pharmaceutical firms and are wary of patented drugs' high costs. As a result, brawls over patent protections and prices have broken out from Brazil to Thailand.</p><p>The fight is particularly fraught in India. It has the world's biggest generics industry, an adolescent patent law, growing demand for medicines and an inability to pay for all of them. <a href="http://www.pwc.com/jp/ja/japan-knowledge/archive/assets/pdf/pharma-2020-vision-to-decision.pdf">PwC</a>, a consultancy, expects Indian drug sales to grow from $16 billion in 2011 to $49 billion by 2020. Nearly three quarters of the sales come from generic drugs, and this is unlikely to change, reckons PwC. The Supreme Court ruling, and another one last month, help to explain why.</p><p>Innovative drug companies have faced two key questions in India. First, will India's young patent regime, in place since 2005, provide the same protection as those in America and Europe? Second, will Indian regulators tolerate high drug prices? The answer to both questions seems to be "no".</p><p>The Supreme Court defended India's right to deny patents to incremental improvements. It ruled that Glivec was merely a new form of an older drug and did not constitute a patentable invention. "This is a huge relief," <a href="http://www.msfaccess.org/about-us/media-room/press-releases/indian-supreme-court-delivers-verdict-novartis-case">said</a> Unni Karunakara, the president of Médecins Sans Frontières, which cares for patients in poor countries. Novartis is less pleased, <a href="http://www.novartis.com/newsroom/media-releases/en/2013/1689290.shtml">declaring</a> that the ruling "discourages future innovation in India."</p><p>The April ruling follows another by an Indian appeals board in March. In that case, the board upheld a decision to let Natco, a generic drugmaker, sell copies of Bayer's patented kidney-cancer drug Nexavar. Bayer had not made the drug available to Indians at a sufficiently low price.</p><p>With these rulings, India has become the most extreme case of a problem plaguing Big Pharma from Berlin to Beijing: how to convince governments and consumers to pay for their drugs. Some companies will continue to seek high prices for worthy medicines. Others may chase sales by lowering prices to boost volumes. Either strategy will carry risks.</p><p>(Photo credit: AFP)</p></div></div></div></span><span class="Apple-Mail-URLShareUserContentBottomClass" style="line-height: 14px !important; color: black !important; text-align: left !important; " applecontenteditable="true"><br></span></span></div>TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-18375686859038486012013-01-26T18:58:00.001-05:002013-01-27T18:30:42.996-05:00Must read: End the FDA Drug Monopoly: Let Patients Choose Their Medicines<h1>
End the FDA Drug Monopoly: Let Patients Choose Their Medicines</h1>
<cite>by <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Doug Bandow</a>, <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">cato.org</a><br />June 11th 2012</cite> <br />
Americans want to reduce health care costs and improve patient care. Congress says it wants to do the same, which is why both houses recently voted to renew drug approval "user fees." But it would be better to strip the Food and Drug Administration of its monopoly control over pharmaceutical development.<br />
<br />
The FDA was created in 1906, before prescription drugs became a leading medical treatment. The 1962 Kefauver-Harris Amendments vastly expanded agency control over drug approval, giving the FDA, which also regulates most food products, cosmetics, vitamin and dietary supplements, the power to determine efficacy as well as safety of new pharmaceuticals.<br />
<br />
Drug discovery is an uncertain business. Unfortunately, new medicines do not appear miraculously, like manna from heaven. Firms typically have to assess between 5,000 and 10,000 substances for every one that survives the extensive testing process and makes it to market. Of those that win approval, 80 percent lose money. Only a few pharmaceuticals pay for the entire development process.<br />
The average cost of developing a new drug runs more than $1 billion, with estimates traditionally ranging between $1.2 and $1.5 billion. The more stringent the FDA controls, the greater the expense. Bernard Munos at InnoThink and <em>Forbes</em> magazine's Matthew Herper recently pegged the development cost much higher.<br />
<br />
Critics complain that these numbers include administrative and marketing costs, but what business, let alone government agency, does not have administrative expenses? And marketing is an investment—drug companies advertise to sell more pills. It would be a strange industry if firms created products at great expense and then locked them away, playing a form of consumer hide and seek.<br />
<br />
All told, Avik Roy of the Manhattan Institute figured that the consequences if unnecessary regulation "are higher-than-necessary health spending and poorer health outcomes. Pharmaceutical companies charge more for their products, in order to recoup their costly and risky investments. And fewer beneficial drugs reach doctors and patients."<br />
<br />
Of course, the FDA claims to protect the public from unsafe, ineffective drugs. But the agency can make two different errors. One is to approve bad products. The other is to block (or delay) good products. Noted Henry Miller of the Hoover Institution: "Public health is harmed when potentially beneficial products are delayed, abandoned, or never tested at all."<br />
<br />
The political penalty for the first mistake is high. Congressmen love a spectacle, and there is no better show than denouncing officials for allowing a dangerous product on the market. The specter of Thalidomide, which resulted in birth defects—but was never released in America—still hangs over drug development. (Ironically, the drug has made a comeback as a treatment for Leprosy.)<br />
<br />
In contrast, the second mistake rarely carries a price. The absence of a good is harder to recognize than the presence of a bad. Richard Merrill, former FDA chief counsel, wrote: "No FDA official has ever been publicly criticized for refusing to allow the marketing of a drug." At least until AIDS emerged as a veritable death sentence most people seemed unaware that there even was a downside to strict pharmaceutical regulation.<br />
<br />
Between 1962 and 1967 the average delay in approval time rose from seven to 30 months. Total drug development time jumped from around three years in 1960 to six years in 1965 and ten years in 1970. The Tufts University Center for Drug Development found little has changed in recent years. Estimates range between 10 and 20 years, most commonly settling around 15 years.<br />
<br />
Economist Sam Peltzman concluded that the introduction of new drugs fell by more than half after Kefauver-Harris. Yet there was no comparable drop in the release of unsafe or ineffective pharmaceuticals or withdrawal of unsafe products from the marketplace. Moreover, Peltzman wrote, the "penalties imposed by the marketplace on sellers of ineffective drugs prior to 1962 seem to have been enough of a deterrent to have left little room for improvement by a regulatory agency," an assessment later backed by economists Henry Grabowski and John Vernon.<br />
<br />
Increasing delays mean more than increased costs. The process slows the release of beneficial pharmaceuticals. Which means dead and suffering patients.<br />
<br />
Years ago analysts began writing about the drug lag created by the FDA. Numerous medicines made it to the European market before they were released in America—drugs which were both safe and effective. Americans did without—or illegally smuggled medicines from overseas. The FDA's slowness did not increase safety: post-approval drug withdrawals were comparable on both sides of the Atlantic. Doctors William Wardell and Louis Lasagna concluded that "the United States has lost more than it has gained from adopting a more conservative approach." Although the U.S. may have edged ahead of Europe over the last decade, the FDA is still harming rather than enhancing the public safety.<br />
Agency controls over advertising and marketing have a similar effect, reducing the speed with which new treatments by existing products are adopted. It often is not economical for a company to go to the expense of winning approval for additional uses for existing products, especially as a drug's patent life ebbs. However, doctors can prescribe the medicines for any treatment they deem appropriate. Alexander Tabarrok of the Independent Institute reported that the vast majority of pediatric, AIDS, and cancer patients have received off-label prescriptions.<br />
<br />
Yet drug companies are forbidden to advertise these extra benefits. For years the FDA prevented any mention of aspirin's value in preventing heart attacks or even the federal Centers for Disease Control and Prevention's recommendation that women take folic acid supplements to reduce birth defects. Abbott recently paid $1.6 billion in fines to settle a Justice Department prosecution for promoting unapproved uses of its drug Depakote.<br />
<br />
Tolls of doctors ranging from cardiologists to oncologists routinely found that a large majority believed that the FDA was too slow to approve new drugs. AIDS added a new political dimension, compelling, in Greenberg's words: "a grudging administrative recognition that the traditional mission neglected the interest of people whose lives were primarily threatened by the absence of treatment, rather than by unidentified harmful side effects of treatment."<br />
<br />
But that recognition remains grudging. The agency periodically has become more industry friendly—regulatory bodies frequently are "captured" by those they supposedly are overseeing, to the detriment of consumers. But this process has not much helped get drugs to market.<br />
<br />
FDA procedures were changed to speed release (through "Accelerated Approval") of drugs designed to treat life-threatening conditions. The improvement was real, but limited. <em>Nature Biotechnology</em> pointed out that only a handful of drugs have gone through the process and that "in recent years, FDA has been ratcheting up the requirements." Moreover, this initiative did nothing for the vast majority of drugs which benefit the vast majority of people.<br />
<br />
The human toll has been high. Pharmaceuticals have significantly improved people's lives. But much more could be done. Where treatments are few the sick and dying feel helpless. For instance, the <em>Wall Street Journal</em> reported on patients with Lou Gehrig's disease who, "frustrated by the slow pace of clinical drug trials or unable to qualify, are trying to brew their own version of an experimental compound at home and testing it on themselves."<br />
<br />
The greatest harms from drugs typically result from misuse or misprescribing rather than unexpected side effects. The deadliest latter problem pre-1962 involved Elixir Sulfanilamide, which killed 107 people. Through 1980, figured Dale Gieringer, an expert in drug regulation, the highest death toll may have been 3500 dead around the world due to Isoproterenol, an inhaler for asthmatics. (Thalidomide resulted in 10,000 or more birth defects, but no deaths.)<br />
<br />
In recent years significant drug problems have typically involved deaths in the scores. In 2007 Merck settled roughly 3500 death claims charged to the painkiller Vioxx without admitting that the drug was responsible (the company won 11 of 16 individual cases before agreeing to general settlement). Moreover, argued Gieringer: "there have been only one or two major drug accidents that could have been averted through stricter premarket testing, and one or two that could not have been prevented."<br />
The death toll from over-regulation is far greater. Pharmacologist William Wardell concluded that the five year delay in allowing the hypnotic Nitrazepam to be used in America (after Britain's approval) cost 3,700 lives. He believed that the FDA also cost thousands of lives by preventing the sale of the first beta-blocker Propranolol for three years after it was available in Europe, and another seven years before it could be used for its most useful purposes. Sam Kazman of the Competitive Enterprise Institute (CEI) figured the annual beta-blocker toll at 17,000. Overall, he wrote, "as many as 100,000 people may have died waiting for FDA to act."<br />
<br />
Indeed, CEI warned that the agency has delayed the arrival of a host of live-saving medicines: ancrod, citicoline, ethyol, femara, glucophage, interleukin-2, navelbine, lamictal, omnicath, panorex, photofrin, prostar, rilutek, taxotere, transform, and vasoseal. While the specifics vary, the combined human cost has been high. Gieringer explained: "The benefits of FDA regulation relative to that in foreign countries could reasonably be put at some 5,000 casualties per decade or 10,000 per decade for worst-case scenarios. In comparison… the cost of FDA delay can be estimated at anywhere from 21,000 to 120,000 lives per decade. These figures would seem to support the conclusion that the costs of post-1962 regulation outweigh benefits by a wide margin, similar to Peltzman's results of a 4:1 cost-benefit ratio for the 1962 amendments."<br />
<br />
Some illnesses rob people of many of the pleasures of life rather than of life itself. Noted Gieringer: the foregoing estimates "completely ignore the drug benefits of reduced morbidity from crippling strokes, polio, and other nonfatal illnesses, the value of which in many cases may be comparable to that of life itself."<br />
<br />
Even harder to assess are the lost benefits from drugs not developed or marketed. Tabarrok pointed to the problem of "orphan diseases," rare conditions affecting relatively few people. The higher drug development costs, the less likely products will be produced for these ailments. He wrote: "Thus, millions of Americans have few or no therapies available to treat their diseases because of increased costs of drug development brought about by stringent FDA 'safety and efficacy' requirements."<br />
The FDA is killing people. With kindness, perhaps. But it is killing, nonetheless.<br />
<br />
Obviously, the answer is not to ignore safety. Rather, the regulatory process needs to reflect current scientific opportunities and patient needs. Observed John Lechleiter, the CEO and Chairman of Eli Lilly & Co.: "We can't have a 1950s or 1960s or 1970s regulatory system when we're doing 2011 or 2012 or 2020 science."<br />
<br />
Regulatory reform by the FDA would help. However, Henry Miller warned that "within the current system, regulators' self-interest is not served by the implementation of meaningful change, so real reform is never accomplished." Indeed, of late the agency seems focused on the trivial. Two years ago the FDA proposed requiring movie theaters to release calorie counts for popcorn, only to retreat in the face of popular scorn mixed with political pressure.<br />
<br />
Legislative initiatives for revamping the FDA and speeding drug approval abound. However, more fundamental change is necessary. For instance, Henry Miller would require continued FDA approval, but instruct the agency to anoint competitive "drug certifying bodies" (DCBs), which would actually review drugs. The government could be restricted to judging safety, leaving efficacy up to the marketplace. After all, assessing effectiveness is what markets do every day. Andrew von Eschenbach, a former head of both the FDA and National Cancer Institute, proposed establishing a pilot program allowing drugs "to be approved based on safety, with efficacy to be proven in later trials."<br />
<br />
Better would be to eliminate the FDA's monopoly over drug safety as well. Explained Corinne and Robert Sauer of the Jerusalem Institute for Market Studies: "drugs are expensive not because of a lack of competition among research-based pharmaceutical companies, but because of a lack of competition in the drug approval process."<br />
<br />
One approach would be to allow the sale of pharmaceuticals (and medical devices) approved by the regulatory agencies of other industrialized states. If an industrialized Asian or European nation has released a product to market, it could legally be sold in America, subject to a showing of unreasonable danger.<br />
<br />
Best would be to make the FDA's approval advisory. If you only trust the U.S. government, then only take medicines (or use medical devices) endorsed by the agency. Otherwise consider the opinion of doctors, hospitals, and other medical providers, as well as look for certification by public or private organizations. The Sauers suggest leaving approval to private DCBs.<br />
<br />
They point to a similar system which operates to regulate the sale of kosher food. A private agency, Underwriters' Laboratory, also tests electrical products. No law requires review, but wholesalers, retailers, and customers prefer products so certified. UL even helps local governments develop building codes.<br />
<br />
Organizations interested in patient care could undertake or promote testing of new medicines. For instance, the American Hospital Formulary Service Drug Information manages a comprehensive drug database; the ECRI Institute researches patient care; the National Comprehensive Cancer Network, an organization of cancer hospitals, publishes a reference of cancer drugs; and the United States Pharmacopoeia Convention sets standards for prescription and over-the-counter drugs. Providers or provider associations (such as the American Medical Association and American Hospital Association) or insurers could pay to have products reviewed.<br />
<br />
The industry might even establish and fund an organization, which would be left to operate independently. Reputation would be everything for an evaluation agency: if seen as a tool of industry no one would believe its assessments. And no association or company would have an incentive to fund it.<br />
<br />
The most important principle for reform should be freedom of choice. People, in consultation with their doctors and other medical professionals, should be allowed to make different decisions reflecting their unique medical needs and risk assessments.<br />
<br />
In many cases there is no one right medical decision. The FDA recently stripped Avastin of approval for use in treating breast cancer. Medical professionals disagree on the drug's value. Two recent studies found that Avastin had some value in treating metastatic breast cancer. One concluded that adding the medicine resulted in "significantly higher rates of pathologic complete response." Maybe the benefits don't justify the cost. However, the government should not deny this treatment option to people who are desperately ill with a disease that is most often fatal.<br />
<br />
The current system presumes a trade-off between efficiency and safety. But Henry Miller argued that "If we can end regulatory excesses, introduce competition into regulatory oversight, and redirect government involvement to those few activities where a central, monopolistic role is essential, more patients will benefit from a greater number of drugs made available to them in a timelier way."<br />
Who should decide what drugs to use? Patients. They need advice, not diktats. Congress should strip the FDA of its regulatory monopoly over pharmaceuticals and medical devices. The public health would benefit.<br />
<br />
<!--ENDLESS--> <br />
Original Page: <a href="http://pocket.co/sG3fL">http://pocket.co/sG3fL</a><br />
Shared from <a href="http://readitlaterlist.com/">Pocket</a>TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-11606818514481902602013-01-20T16:07:00.001-05:002013-01-27T18:27:50.881-05:00InVitae, Led by Randy Scott, Goes ‘All-in’ For Genomic Diagnostics<h1>
<span style="-webkit-composition-fill-color: rgba(175, 192, 227, 0.230469); -webkit-composition-frame-color: rgba(77, 128, 180, 0.230469); -webkit-tap-highlight-color: rgba(26, 26, 26, 0.296875); font-size: medium; font-weight: normal;">Very, very cool new venture. I like their approach, and like the fact that the GHDX folks are both recycling and extending.....</span></h1>
<h1>
InVitae, Led by Randy Scott, Goes 'All-in' For Genomic Diagnostics</h1>
<cite>by <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Luke Timmerman</a>, <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">xconomy.com</a><br />January 18th 2013</cite> <br />
<h5>
<nobr><a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Follow @ldtimmerman</a></nobr></h5>
You could call <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Randy Scott</a> an E.F. Hutton for the genomics business. People listen when the co-founder and former CEO of Genomic Health talks. And Scott isn't just talking. He's gone "all-in," putting his time, and a significant amount of his own money, into a new San Francisco company called <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">InVitae</a>. The plan is to develop a kind of dream diagnostic test that would have been quite unrealistic a couple years ago.<br />
<br />
"We want to aggregate all the world's genetic tests into a single assay, for less than the cost of a single assay today," Scott says. He adds: "It's kind of outrageous, but it's eminently doable."<br />
InVitae—which is Latin for "in-life" and pronounced In-VEE-tay—has stayed stealthy in its early days. But that's changing this year, as the company has gotten certified to run a central diagnostics lab and it's gearing up for its initial commercial push.<br />
<br />
The company, which combined assets last year from Redwood City, CA-based Genomic Health (NASDAQ: <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">GHDX</a>) and Locus Development, has pulled in $37 million to date from investors that include Genomic Health, Thomas McNerney & Partners, and Scott himself. Scott started moving in this direction <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">back in February</a>, when Genomic Health formed InVitae as a new subsidiary with him as CEO. Six months later, <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">in August</a>, he jumped ship completely for the new company, resigning his Genomic Health board seat. InVitae, which took in <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">$30 million of investment in November</a>, has grown quickly to assemble a team of 40 employees.<br />
<br />
"Having done startups before, I'm a big believer that you've got to be all-in," Scott says. "If you want to start something from scratch and compete in today's world of healthcare, it should consume 150 percent of your time."<br />
<br />
The goal of InVitae, in its early days, is to help geneticists to look broadly for rare, inherited genetic disorders (aka Mendelian disorders). There are thought to be about 1,500 of these rare conditions, which are often hard to diagnose. Sometimes these diseases prompt what Scott calls "medical odysseys" and are only diagnosed after physicians take stabs in the dark by running existing single-gene or multi-gene tests that can only answer narrow questions, and cost several hundred dollars apiece.<br />
InVitae's plan is to start small, and build from there. While the usefulness of information from consumer-oriented genetics companies (<a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">23andMe</a>, Navigenics) has long been questioned in the medical community, InVitae has instead focused on looking for the small number of genetic abnormalities and variations that are clearly linked to a disease that physicians treat.<br />
<br />
InVitae can't yet run a comprehensive screen of all 1,500 Mendelian disorders, and deliver a report that definitely says whether a patient has one. It has spent its early days establishing a central diagnostics lab, equipped with Illumina sequencing machines, and combing through publicly available scientific literature to find the strongest links between genetic abnormalities and medical disorders. So far, for the small group of beta customers, the test can scan for 150 of those disorders, at a price of $1,500. If a physician wants to ask a narrower question—like whether a patient has one of the many genetic variations that lead to cystic fibrosis—the sequencing service and price can be tailored accordingly, Scott says. The samples get sent in to InVitae's lab, and a report comes back to the physician a few days later.<br />
<br />
While a huge amount of information on these gene-disease links is in the public domain, it's full of conflicting information, and isn't curated. Just going through the public literature to try to find the valuable links between genomic abnormality and disease is a daunting task.<br />
<br />
"What's happened historically is kind of a tragedy of the commons," Scott says. "People put all the variants they study into the public domain, but nobody curates it, cleans it up." The InVitae team, in doing the curation, has found "enormous errors" that it is weeding out of its central database. The variants in the InVitae database are ones that, Scott says, "accurately predict disease."<br />
<br />
The time is right for such a test, Scott says, because physicians are becoming increasingly interested in not just single-gene or multi-gene diagnostics, but broader genomic tools that can aid in medical diagnosis. Over time, as sequencing gets even cheaper and more scientific links between gene variants and disease are established, InVitae hopes to cast a wider net. In the near future, InVitae hopes to make a single test that scans for all 1,500 known inherited (Mendelian) genetic disorders, and either rules them in or out for an individual patient.<br />
<br />
Further in the future—maybe 10 or 20 years, in Scott's view—newborns will get their full genomes sequenced to look not just for clear inherited disorders, but to delve into predispositions and likelihoods of developing complex diseases that involve multiple genes and environmental factors. Many of these conditions could be spotted early, and managed, long before they start manifesting themselves through mysterious symptoms later in life, Scott says. Disorders like Klinefelter's syndrome, and hemochromatosis—a common iron-overload condition—can be detected today, but often aren't, because there's rarely an obvious reason to look. But InVitae expects that its tests will be able to routinely spot those disorders during its sweeping tests, and those findings could help physicians successfully treat the condition early in life before symptoms cause trouble.<br />
<br />
"One of the goals for InVitae is to help manage your genome for life, and do it in a medically oriented way," Scott says.<br />
<br />
Dietrich Stephan, the founder and CEO of SVBio, another aspiring "clinical genomics" entrepreneur, says he's closely tracking the competition and knows that InVitae has hired a number of experienced people from his previous company, Navigenics. His company is also looking at Mendelian disorders as the first of many genomic diagnostic opportunities.<br />
<br />
"I have the highest regard and respect for Randy. I'm looking at it as validating what we're doing," Stephan says. "There's plenty of room in the market for more than one company. Physicians are starved for this."<br />
<br />
The business at InVitae is quite different from Genomic Health, which markets specific diagnostic tests for breast and colon cancer. Those tests must be built on a basis of company-sponsored clinical trials that demonstrate the value of the test for both physicians and payers. By leaning on well-scrubbed, publicly available data from studies of gene variants and rare disorders, InVitae doesn't need to run lots of expensive clinical trials on its own, Scott says.<br />
<br />
The concept for InVitae isn't actually that new—it was one of the earliest ideas that Scott flirted with back in 2000, in the founding days of Genomic Health. The concept was about what he calls the combination of "Moore's Law, Metcalfe's Law, and the law of finite genomes."<br />
<br />
Back then, he saw DNA sequencing tools were on track to get exponentially better, faster and cheaper. The tools would create a flood of DNA data, which isn't worth much in isolation, but which could be <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">much more valuable when widely shared</a> and compared. The opportunity would someday be within reach, because there are only so many genes and mutations to study that will be really useful for healthcare.<br />
<br />
For years, Scott worked on it before concluding that the technology needed to get better. "It was much too early."<br />
<br />
That's changed now, as instrument makers are racing to develop technology that can sequence entire human genomes for $1,000, in as little as one day. Genomic Health saw the opportunity, invested some in it for a while, but spun it out as the company has other priorities going with specific tests for breast, colon, and prostate cancer.<br />
<br />
The market opportunity for something like InVitae could be in the "many billions," Scott says. Mendelian diseases are one place to start, but even bigger markets could emerge in scouring the genome for cancer. Cambridge, MA-based Foundation Medicine has gotten off to a fast start, and recently <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">attracted an investment from Bill Gates</a> for a genomic test that looks for abnormalities in 200 different cancer-related genes. While Foundation looks for so-called somatic mutations that arise in tumor samples later in life, InVitae envisions looking broadly at the genome for inherited variants that are thought to raise the risk of cancer, Scott says.<br />
<br />
How big the various genomic diagnostic markets could be is still anybody's guess, but Genomic Health alone makes more than $200 million a year, largely off one specific test for breast cancer recurrence. The underlying sequencing technology continues to get faster and cheaper, making it possible for scientists to ask more and more questions that enrich the public databases that InVitae will rely on, and contribute to, as its business grows.<br />
<br />
Price, of course, will be a huge factor in determining how widely the tests are adopted, and how well they will be embraced by insurers. InVitae's service will rise and fall at various points, as technology drives things down, and valuable new features drive things back up, Scott says. Competitors, both publicly declared and stealthy, will also play a role in determining just how high or low the prices will be.<br />
<br />
Scott, during a short interview at the JP Morgan Healthcare Conference in San Francisco, seemed to relish all the uncertainty and variables heading his way in the new venture. "We're really just entering the world, in 2013, where these types of products are coming to market," he says. <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152"></a><br />
<!--ENDLESS--> <br />
<br />
Original Page: <a href="http://pocket.co/sGbA2">http://pocket.co/sGbA2</a><br />
Shared from <a href="http://readitlaterlist.com/">Pocket</a><br />
<br />
<br />TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-69705014327833988352013-01-20T15:18:00.001-05:002013-01-27T18:26:30.496-05:00Life Technologies Said to Be in Takeover Talks- Bloomberg<h1>
<div style="-webkit-composition-fill-color: rgba(175, 192, 227, 0.230469); -webkit-composition-frame-color: rgba(77, 128, 180, 0.230469); -webkit-tap-highlight-color: rgba(26, 26, 26, 0.296875); font-size: medium; font-weight: normal;">
This article smells like it was planted to chum the waters for a deal.<br />
<br /></div>
<div style="-webkit-composition-fill-color: rgba(175, 192, 227, 0.230469); -webkit-composition-frame-color: rgba(77, 128, 180, 0.230469); -webkit-tap-highlight-color: rgba(26, 26, 26, 0.296875); font-size: medium; font-weight: normal;">
I think that LIFE is generally fairly valued by the markets, so they're going to have to get one of the corporate buyers (Roche, Danaher, etc) excited enough to overpay.(I don't see that happening in the case of very-disciplined Danaher, or most of the other companies named, but then again, I was shocked at what Merck KgA paid for Millipore.)<br />
<br /></div>
<div style="-webkit-composition-fill-color: rgba(175, 192, 227, 0.230469); -webkit-composition-frame-color: rgba(77, 128, 180, 0.230469); -webkit-tap-highlight-color: rgba(26, 26, 26, 0.296875); font-size: medium; font-weight: normal;">
Also, as I've mentioned before, the decision of whether or not to put a company up for sale very often is solely a question of whether or not a CEO wants to move on. (This is especially true in banking M&A), so I guess Greg Lucier is ready to move on to his next challenge. I wish more Boards in that event would decide to turn the company over to a new CEO internally sourced rather than undertaking a sale. </div>
</h1>
<h1>
Life Technologies Said to Be in Takeover Talks- Bloomberg</h1>
<cite>by Cristina Alesci, <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">bloomberg.com</a><br />January 18th 2013 11:01 PM</cite> <br />
<a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Life Technologies Corp. (LIFE)</a>, a maker of DNA-sequencing equipment and laboratory materials, is in discussions with private-equity firms and health-care companies about a potential sale of the company, according to people familiar with the process.<br />
<br />
<a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Blackstone Group LP (BX)</a> and <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">KKR & Co. (KKR)</a> are among four private- equity firms weighing bids, said two people, who asked not to be named because the discussions are confidential. Health-care companies also have expressed interest in a takeover and potential suitors have until late January to submit offers, the people said. Life said yesterday it had hired Deutsche Bank AG and Moelis & Co. to assist in a strategic review of the company.<br />
<br />
The Carlsbad, California-based company has a current market value of about $10.5 billion, after shares rose yesterday to their highest-ever price based on takeover speculation. Life may sell for about $13 billion, with a buyout fund writing an equity check of $4 billion to $5 billion for the deal, one of the people said.<br />
<br />
Life's "valuation has been relatively depressed," <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Ross Muken</a>, an analyst with ISI Group, said in a telephone interview. "They've had an ongoing battle in terms of messaging, positioning and capital deployment."<br />
<br />
Life <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">trades</a> at about 15 times estimated earnings, compared with about 33 times for <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Illumina Inc. (ILMN)</a>, its competitor in DNA- sequencing machines.<br />
<br />
Life's shares rose 11 percent to $60.79 at the close yesterday in New York, the biggest single-day gain in almost four years and the highest value since shares started trading publicly in February 1999.<br />
The company's board retained Deutsche Bank and Moelis "to assist in its annual strategic review," Life said in a statement. "The board of directors has not decided on any specific course of action."<br />
The company's statement implies Life has "potentially received an offer from an acquirer, is contemplating a LBO or is potentially in the process of shopping the company for a strategic buyer," William Quirk, an analyst with Piper Jaffray & Co., wrote in a research note. He cited <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Roche (ROG)</a> Holding AG, <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Thermo Fisher</a> Scientific Inc. and <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">General Electric Co. (GE)</a> as potential strategic buyers.<br />
Gene-sequencing companies such as Life and San Diego-based Illumina are attractive takeover targets because their technology can be used to provide a blueprint of a person's DNA, information that may eventually be used to diagnose disease, identify the risks of certain conditions or better target medicines.<br />
Roche, the world's biggest maker of cancer drugs, failed last year in a hostile bid for Illumina. Life is more diversified than Illumina, with "slow-growth research consumables" dominating its portfolio, said Quirk. For that reason, "we believe an acquirer interested in the faster- growing next-gen sequencing business has better options."<br />
<br />
ISI Group's Muken put the possibility of a leveraged buyout at 10 percent, pegging the price at $55 to $65 a share. He said a sale to a strategic buyer, such as a large pharmaceutical firm or equipment company like <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Danaher Corp. (DHR)</a>, may have a 40 percent chance of occurring, at $60 to $70 a share.<br />
<br />
Roche backed away from its $6.7 billion bid for Illumina last year after investors asked for a higher offer. Roche doesn't comment on rumors or speculation, Daniel Grotzky, a spokesman for the Basel, Switzerland-based company, said by e- mail in response to a question about Life.<br />
<a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">Seth Martin</a>, a spokesman for GE, said the company doesn't comment on rumors or speculation. Ron O'Brien, for Thermo Fisher, declined to comment. Matt McGrew, chief of <a href="http://www.blogger.com/blogger.g?blogID=8770049802106489152">investor relations</a> for Danaher, couldn't be reached for comment.<br />
<br />
<!--ENDLESS--> <br />
Original Page: <a href="http://pocket.co/sGbVD">http://pocket.co/sGbVD</a><br />
Shared from <a href="http://readitlaterlist.com/">Pocket</a><br />
<br />
<br />TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-81960080970033772992012-10-04T13:55:00.001-04:002013-01-27T18:17:37.350-05:0010 Truths (or Fictions) About Virtual Biotech Startups - FierceBiotechGreat, great series of articles from the FierceBiotech team:
<br />
<br />
<a href="http://www.fiercebiotech.com/special-reports/10-truths-or-fictions-about-virtual-biotech-startups?utm_medium=nl&utm_source=internal">http://www.fiercebiotech.com/special-reports/10-truths-or-fictions-about-virtual-biotech-startups?utm_medium=nl&utm_source=internal</a>TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-77946225070310464302012-09-30T06:18:00.001-04:002013-01-27T18:18:31.686-05:00Genomes-R-Us: Is BGI now Complete?<div class="article-content entry-content" itemprop="articleBody" style="clear: both; margin: 10px auto 5px; outline: none; padding: 0px; text-align: justify;">
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">Here's a post-Morton on Complete Genomics (GNOM). I'm surprised that BGI didn't go public on the basis of CGOM's public listing. I guess that they don't want the people who put up $1.5B to finance BGI to find out that BGI is worth ony a fraction of that amount.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">Genomes-R-Us: Is BGI now Complete?</span></div>
<cite style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);"></cite><br />
<div style="text-align: -webkit-auto;">
<cite>September 25th 2012</cite> </div>
<br />
<h5 style="font-weight: bolder; margin: 1.5em 0px; padding: 0px;">
</h5>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">The sad endgame in the acquisition of <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">Complete Genomics</a> (NASDAQ: <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">GNOM</a>) came last week: having failed to create a sustainable business, CGI was put up for sale in June of this year,<a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">culminating in a takeover</a> by sequencing powerhouse <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">BGI</a> for $117.6 million in cash plus $30 million in bridge financing.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">Behind that headline is a fascinating story: a U.S. company losing despite being right about its market; a Chinese company succeeding by vigorous price competition and then buying its rival; and a glimpse of the future of genomics-driven medicine.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">On the surface, the sale of Complete Genomics looks like a case of overreach by the company's investors and management coupled with poor execution. Complete, founded in 2005, had early on identified a superior business model for the coming era of cheap and frequent sequencing: take the sequencing activity and much of the interpretation out of the hands of hospitals and other healthcare providers and instead provide it on an outsource basis—both the sequence data itself as well as the all-important interpretation. For an apt analogy, think of Google's core search business: why own a server farm when what you need are the search results?</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">I strongly remember meeting the late, visionary venture capitalist Alex Barkas of Prospect Ventures at the JP Morgan Healthcare Conference in early 2008 and hearing him forecast a glorious future for Complete Genomics. Even though the market was at that time buzzing about the next high-speed sequencing technology play, Pacific Biosciences (NASDAQ: <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">PACB</a>), Barkas was supremely confident that CGI's innovative business model would rule the day. That vision, driven by Complete Genomics CEO Cliff Reid as well as by Barkas and other investors, brought in VC and public investment of more than $250 million. The company went public at $9 a share and sold for as much as $17 a share before plummeting into the $2 a share range, where PacBio also now languishes. BGI's purchase price correlates to $3.15 a share.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">There were some momentary triumphs along the way, including technical breakthroughs, such as increasing the accuracy of sequencing. But, as <em>Technology Review</em> <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">put it</a>, "Though a 2011 paper<a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">published</a> in <em>Nature Biotechnology</em> found that Complete Genomics produced more accurate DNA data than competitors, superior accuracy never translated into financial success." CGI scored some small commercial successes along the way, such as <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">landing</a> the Mayo Clinic as a client in February of this year. Along the way, CGI was able to drop the price of a full human genome sequence to $4,200 in 2011, down from $12,000 in 2010.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">But CGI's revenues and, presumably, its margins dropped along with the price and the company never made up the difference on volume. Even worse, the company lagged in processing the genomes it had promised to sequence. The backlog in the end numbered in the hundreds of genomes. And even if CGI had been able to keep up with the influx of genomes it had, the customers did not come in sufficient numbers to create growth. A CGI business development executive told me in February that</span></div>
<h5 style="font-weight: bolder; margin: 1.5em 0px; padding: 0px;">
</h5>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">(Page 2 of 3)</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">the only thing that would drive a higher stock price would be when the company proved its value and thereby showed big revenue gains. That executive has since left the company and, far from being able to build a sustainable business around this model, CGI first had to <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">downsize</a> and then had to be sold. And the buyer, in what must seem to insiders like a bitter irony, is a former competitor, the U.S. subsidiary of Shenzhen, China-based BGI.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">BGI is not just any competitor. In fact, BGI had arguably represented the biggest obstacle standing in the way of Complete's success. As CGI tried to increase its market share by cutting prices, BGI responded by cutting them still further. BGI, using sequencers from Illumina, had a lower cost of capital due to the patience and strategic orientation of its investors. Like <a href="http://amazon.com/" style="-webkit-transition: color 0.3s; display: inline; outline: none; text-decoration: none;">Amazon.com</a>, the company and its investors focused not so much on quarterly earnings statements, but rather on BGI's market share. They chose to operate BGI at what must have been a loss for several years and succeeded at driving CGI to the auction block. (BGI was founded in 1999, and in 2010 it received $1.5 billion in funding from the China Development Bank to expand its operations, <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">according to</a> Isaac Ro of Goldman Sachs.) BGI apparently succeeded in a big way. In January, 2011, <em>Nature</em> <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">estimated</a> that of the 30,000 human genomes that would be sequenced that year, BGI would be responsible for 10,000 to 20,000 of them. The lower prices were good for customers but bad for competitors (bye, bye, CGI).</span></div>
<h1 style="font-weight: bolder; margin: 0.67em 0px; padding: 0px; position: relative; text-align: -webkit-auto;">
<span style="font-size: small;"><span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">A transition waiting to happen</span></span></h1>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">So if BGI emerged triumphant from the bruising price war, why did it buy its former rival? Several reasons, all of them interesting. Like every other player in the commercial world of genomic sequencing and analysis, BGI is on a journey from research to clinical applications. BGI hopes that the market finally (finally) expands once sequencing becomes a routine clinical activity ordered by physicians and reimbursed by insurance companies. In other words, like CGI was, BGI is eagerly preparing for sequencing to become part of routine disease diagnosis and determination of therapy.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">The transition to clinical adoption of sequencing has been "just about to happen" for the last five or six years. If and when it does (and I am still betting that it will), BGI needed to be prepared. It was facing several obstacles, all of which can be overcome or at least reduced with the pickup of CGI:</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);"><strong>Reduce or eliminate dependence on Illumina:</strong> Illumina is <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">increasing and speeding up</a> its service offerings. BGI had become dependent on sequencers from Illumina, the market leader in sequencer sales with over 60 percent share, which had provided most of its 100-plus machines. (According to a research note published by Wall Street analyst Peter Lawson of Mizuho on Monday, Sep. 24, Illumina's market share has actually reached 66 percent.) Now that Illumina is moving into sequencing-as-a-service in a much bigger way, it will be more of a competitor to BGI. Thus, owning CGI and its proprietary sequencing technology (and different reagent suppliers) will give BGI an advantage.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);"><strong>Improve turnaround time:</strong> Shipping samples across the Pacific was not an efficient way for BGI to deliver data to customers in the U.S. market. Research institutes might have put up with it but clinicians will not. By buying Complete Genomics and its California-based sequencing "factory," BGI is moving closer to its customers.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);"><strong>Add customers and capacity:</strong> BGI picks up not just CGI's customers (like the Mayo Clinic) but also its 25 or so sequencers. Isaac Ro of Goldman Sachs last week <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">told GenomeWeb</a> that the deal accelerates BGI's expansion into the U.S. and gives it "an immediate infrastructure and service offering that will complement the facilities in China." Former CGI developer Zhanzhi Hu told me<a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;"></a></span></div>
<h5 style="font-weight: bolder; margin: 1.5em 0px; padding: 0px;">
</h5>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">(Page 3 of 3)</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">in a phone interview that "If CGI has a healthy factory, it could crank out 1000 genomes a month—a not insignificant number." BGI will need that capacity and more. A reliable industry source told me that the Mayo Clinic deal is expected to require sequencing of <em>200,000</em> human genomes over the next five years. Too bad for CGI that they could not hang on long enough to do all that sequencing!</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);"><strong>Become a clinical laboratory:</strong> This is perhaps the most important reason. CGI applied in July to the U.S. government to attain status as a CLIA lab. The decision, expected to be positive, should come in late 2012 or early 2013. The decision to buy CGI echoes the recent $50 million acquisition of former personal genomics company Navigenics by the second-largest sequencing manufacturer Life Technologies (NASDAQ <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">LIFE</a>). In its acquisition announcement, LifeTech <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">declared</a> that it will shut down the Navigenics consumer business while maintaining its CLIA lab. (Illumina has had a CLIA lab since 2009).</span></div>
<h1 style="font-weight: bolder; margin: 0.67em 0px; padding: 0px; position: relative; text-align: -webkit-auto;">
<span style="font-size: small;"><span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">Growing up and being clinical</span></span></h1>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">If sequencing goes clinical, BGI will be able to play sooner and better based on its pickup of CGI. Although BGI already has a U.S. sales presence, it has no way of serving clinical customers in the United States. If the CLIA lab designation comes through, then BGI will be able to sell clinical sequencing right away. One of the immediate drivers of the deal may have been Illumina's predicted hesitancy (according to my industry sources) to sell clinical-rated instruments to BGI rather than research-only instruments once Illumina receives its expected 510(k) clearance from FDA.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">There is also a cultural aspect. BGI has built a stellar reputation as a provider of genome sequence data. But it is not a U.S. company. By keeping CGI up and running as a U.S. subsidiary, BGI can—assuming that the deal goes through—sell its services more easily as it competes with U.S. players like Illumina and LifeTech.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">The race for improved sequencing hardware will not slow down. But as this acquisition shows, the more interesting battlefield, at least for the healthcare field, is in the interpretation of clinically obtained genomic data. The same week that CGI was acquired, Foundation Medicine <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">secured a $42.5 million financing</a> (funded in part by major clinical diagnostics players Roche and Laboratory Corporation of America) to pursue forward-looking genomic medicine in oncology; and the University of Texas M.D. Anderson Cancer Center <a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;">announced</a> an up to $3 billion "Moon Shots" initiative to significantly improve cancer care outcomes, in part by paying closer attention to genomic data.</span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">Clinical sequencing is coming, first in diagnosing especially pediatric diseases of unknown origin and in oncology, then later in gastrointestinal disease (gut microbes…), and perhaps even, much later, in population screening. It just (barely) did not arrive in time to make a success of Complete Genomics. I suspect that BGI and its patient investors will have a better chance.<a href="" style="-webkit-transition: color 0.3s; display: inline; outline: none;"></a></span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">Original Page: <a href="http://xconomy.com/boston/2012/09/25/genomes-r-us-is-bgi-now-complete/" style="-webkit-transition: color 0.3s; display: inline; outline: none; text-decoration: none;">http://xconomy.com/boston/2012/09/25/genomes-r-us-is-bgi-now-complete/</a></span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">Shared from <a href="http://readitlaterlist.com/" style="-webkit-transition: color 0.3s; display: inline; outline: none; text-decoration: none;">Pocket</a></span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);"><br /></span></div>
<div style="margin: 1em 0px; outline: none; padding: 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);"><br /></span></div>
</div>
<div class="article-footer" style="clear: both; margin: 0px; outline: none; padding: 0px; text-align: center;">
<div class="publish-info" style="margin: 0px; outline: none; padding: 5px 0px; text-align: -webkit-auto;">
<span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);">Posted <abbr class="time published" itemprop="datePublished" style="border: none; margin: 0px; outline: none; padding: 0px;" title="2012-09-27T19:55:00.000Z">2 days ago</abbr> by <a class="url fn" href="http://www.blogger.com/profile/04755932720295950358" itemprop="author" rel="author" style="-webkit-transition: color 0.3s; outline: none; text-decoration: none;">synbio</a></span></div>
<div style="text-align: -webkit-auto;">
<br /></div>
<div class="share-controls delay" data-defer="true" data-delay="1000" style="-webkit-composition-fill-color: rgba(175, 192, 227, 0.230469); -webkit-composition-frame-color: rgba(77, 128, 180, 0.230469); -webkit-tap-highlight-color: rgba(26, 26, 26, 0.292969); -webkit-text-size-adjust: auto; background-color: white; display: inline-block; font-family: 'Helvetica Neue Light', HelveticaNeue-Light, 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; margin: 10px 5px; outline: none; overflow: hidden; padding: 0px; white-space: nowrap;">
</div>
</div>
TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com1tag:blogger.com,1999:blog-8770049802106489152.post-53901830585733012542012-09-28T04:34:00.001-04:002013-01-27T18:19:32.741-05:00Big ego VC says Pharma needs more big ego VCs<div>
Read it here:</div>
<div>
<div>
<br /></div>
<div>
<a href="http://www.xconomy.com/san-diego/2012/09/27/kinsella-redux-charting-a-way-back-for-life-sciences-startups/?single_page=true">http://www.xconomy.com/san-diego/2012/09/27/kinsella-redux-charting-a-way-back-for-life-sciences-startups/?single_page=true</a><br />
<br />
I'm not convinced that venture returns are meaningfully impacted by the venture partner involved. In the article above, a big ego VC wistfully urges that his sector return to the glory days. One of his funds from 15+ years ago is offered as evidence that he's brilliant and Big Pharma is stoopid.</div>
<div>
<br /></div>
<div>
Not that Big Pharma is blameless, but there are better explanations for declining returns even as drug discovery has gotten more capital efficient. Here's a few that occurred to me:</div>
<div>
<br /></div>
<div>
1) VC's own movement away from investing in early technologies to later stage deals. VCs basically don't do old-fashioned $500,000 seed stage deals anymore. They're now all about financing companies graduating to Phase II. Gee, Mr. Kinsella, I wonder why there aren't as many early-stage companies.</div>
<div>
<br /></div>
<div>
2) the hangover from VC over investment in the early genomics era. Remember the year 2000 hype behind genomics companies like HGSI, Millennium, and others? Yeah, I can't imagine why Pharma stopped trusting VC.</div>
<div>
<br /></div>
<div>
3) the rotation in investing strategy from FIDDCo (fully integrated drug discovery companies) and platform technologies to target driven companies each based on a small amount of closely-related leads. </div>
<div>
<br /></div>
<div>
4) a lack of public market liquidity for small cap biotech, partly influenced by structural changes (like increased financial regulation reducing the attractiveness of IPOs), but more driven by increasing VC fund sizes. VCs are paid based on assets under management (size of fund = size of paycheck), and with larger fund, it is less economical to make smaller, earlier investments, which also require longer holding times, so VCs moved their money towards PIPES - investments in already-public companies.</div>
<div>
<br /></div>
<div>
There's four reasons generated in about 10 minutes. I'm sure I could come up with 10 more if I spent another hour on the idea, but I'd hate to accidentally give any credence to VC vanity.</div>
<div>
<br /></div>
<div>
Sent from Pocket - <a href="http://readitlater.com/go?src=email">Get it free!</a></div>
</div>
TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-68345495903877482342012-09-24T16:13:00.000-04:002013-01-27T18:20:07.091-05:00Venture firms see signs of rebirth in life sciences<div>
Here's some reasons to be hopeful that the early-stage life science sector is on the upswing. (though i am skeptical that the e-health ventures will deliver (in general.) investors are bringing dot-com growth expectations to regulated markets where behavior doesn't change fast. (And i'm speaking of consumer, practitioner, and payor behavior.)</div>
<div>
<div>
<br /></div>
<div>
<a href="http://www.reuters.com/article/2012/09/24/us-venture-capital-life-sciences-idUSBRE88N0EK20120924">http://www.reuters.com/article/2012/09/24/us-venture-capital-life-sciences-idUSBRE88N0EK20120924</a><br />
<br />
Sent from Pocket - <a href="http://readitlater.com/go?src=email">Get it free!</a></div>
</div>
TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com1tag:blogger.com,1999:blog-8770049802106489152.post-68729594415552357422012-09-19T14:34:00.000-04:002013-01-27T18:21:08.464-05:00Breast cancer drug everolimus 'biggest advance in years'<div>
</div>
<div>
<h1>
<span class="Apple-style-span" style="-webkit-composition-fill-color: rgba(175, 192, 227, 0.230469); -webkit-composition-frame-color: rgba(77, 128, 180, 0.230469); -webkit-tap-highlight-color: rgba(26, 26, 26, 0.292969); font-size: 17px; font-weight: normal;">Maybe mTor therapies WILL have a big impact after all...</span></h1>
<h1>
<span class="Apple-style-span" style="-webkit-composition-fill-color: rgba(175, 192, 227, 0.230469); -webkit-composition-frame-color: rgba(77, 128, 180, 0.230469); -webkit-tap-highlight-color: rgba(26, 26, 26, 0.296875);">Breast cancer drug everolimus 'biggest advance in years'</span></h1>
<cite><a href="">telegraph.co.uk</a> | Sep 7th 2012</cite> <br />
<img src="http://i.telegraph.co.uk/multimedia/archive/02342/CP695J_2342707b.jpg" /> <br />
Up to 8,000 women a year could benefit from everolimus, say specialists, after a trial indicated it could "stall" advanced cancer for about four months longer than persisting with the same treatment.<br />
Three in four women with advanced breast cancer have a form of the disease that is spurred on by the female sex hormone oestrogen.<br />
Many drugs try to block cancer cells from taking up oestrogen or lowering hormone levels, thereby slowing or stopping tumour growth.<br />
However, in time cancer cells work out how to negate the effects of the drugs, become resistant, and tumour growth resumes. Chemotherapy, which can have extremely debilitating side-effects, is usually then the only option.<br />
Everolimus, marketed by Novartis under the brand name Afinitor, is intended for post-menopausal women whose cancers have developed resistance to 'hormonal' treatments.<br />
It works by targeting other proteins in cancer cell, which control how it works and grows.<br />
The drug is so recent that trial results, comparing 485 women given the drug and 239 given a dummy pill, are still coming out. However, after 18 months the differences are already marked.<br />
Among those given a dummy pill and exemestane, which helps prevent oestrogen uptake, tumour growth was stalled by 3.2 months on average. But among those given everolimus and exemestane, it was 7.8 months.<br />
Professor Stephen Johnston of The Royal Marsden Hospital in London, said the impact was so large that it was "changing the natural history of the disease".<br />
He described everolimus as potentially the most significant breakthough for advanced breast cancer since the discovery of drugs that lower oestrogen levels, in the mid 1990s.<br />
Estimating it could help up to 8,000 women a year, he said: "Everolimus has the potential to redefine the way this common form of advanced breast cancer is treated, and importantly offers women an effective alternative to a chemotherapy regime".<br />
There are possible side effects, notably inflammation of mouth tissue, rash, tiredness and diarrhoea.<br />
But Dr Rachel Greig, of the charity Breakthrough Breast Cancer, said the drug was an exciting development.<br />
She said: "Everolimus is one of the biggest advances in breast cancer treatment in many years.<br />
"This drug could make a massive difference to thousands of patients with advanced breast cancer.<br />
"While this is by no means a cure, it could give patients several extra months of good quality of life with their families.<br />
"Everolimus needs to be assessed by Nice but we are strongly backing it to be made available for those who need it."<br />
<!--ENDLESS--> <br />
Original Page: <a href="http://www.telegraph.co.uk/health/healthnews/9548828/Breast-cancer-drug-everolimus-biggest-advance-in-years.html">http://www.telegraph.co.uk/health/healthnews/9548828/Breast-cancer-drug-everolimus-biggest-advance-in-years.html</a><br />
Shared from <a href="http://readitlaterlist.com/">Pocket</a></div>
<div>
<br /></div>
<div>
<br /></div>
<div>
<br />
<br />
<br /></div>
TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com2tag:blogger.com,1999:blog-8770049802106489152.post-27154179504341434342012-08-29T10:07:00.001-04:002013-01-27T18:21:37.553-05:00Biotech’s Capital Intensity Challenge: A Post-Mortem on 2007’s Biggest Deals<div>
</div>
<div>
Truth from Booth: there is no correlation between the amount of venture capital raised by a biotech and it's ultimate outcome. </div>
<div>
<br /></div>
<div>
I suspect that huge VC rounds just incent management to take on more risks beyond their control.</div>
<div>
<br /></div>
<div>
Read Bruce's full article here: <a href="http://pocket.co/s8kDC">http://pocket.co/s8kDC</a><br />
<br />
Sent from Pocket - <a href="http://readitlater.com/go?src=email">Get it free!</a></div>
<div>
<br />
<br />
<br /></div>
TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-18824568278069357962012-08-20T15:46:00.000-04:002013-01-27T18:22:15.547-05:00Tell Me What’s in My Genome!<div>
</div>
<div>
Couldn't have said it better myself: here's an informed writer analyzing the debate over whether or not you own your genome....</div>
<div>
<br /></div>
<div>
<a href="http://www.slate.com/articles/technology/future_tense/2011/11/genetic_testing_in_the_united_states_may_be_hurt_by_the_fda_s_confusing_policies_.html">http://www.slate.com/articles/technology/future_tense/2011/11/genetic_testing_in_the_united_states_may_be_hurt_by_the_fda_s_confusing_policies_.html</a><br />
<br />
Sent from Pocket - <a href="http://readitlater.com/go?src=email">Get it free!</a></div>
<div>
<br />
<br />
<br /></div>
TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-84889687492164975582012-08-17T16:41:00.000-04:002013-01-27T18:22:59.071-05:00Analyst: The Better Desktop DNA Sequencer May Be Losing The Marketing War<div>
</div>
<div>
Worthwhile read comparing DNA sequencer hardware sales: </div>
<div>
<br /></div>
<div>
<a href="http://www.forbes.com/sites/matthewherper/2012/08/15/analyst-the-better-desktop-dna-sequencer-may-be-losing-the-marketing-war/">http://www.forbes.com/sites/matthewherper/2012/08/15/analyst-the-better-desktop-dna-sequencer-may-be-losing-the-marketing-war/</a><br />
<br />
Sent from Pocket - <a href="http://readitlater.com/go?src=email">Get it free!</a></div>
<div>
<br />
<br />
<br /></div>
TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-81524075287289433292012-07-17T20:06:00.001-04:002013-01-27T18:14:36.491-05:00Q: how do you turn $43M into $10M<div>
</div>
<div>
<span class="Apple-style-span" style="-webkit-composition-fill-color: rgba(175, 192, 227, 0.230469); -webkit-composition-frame-color: rgba(77, 128, 180, 0.230469); -webkit-tap-highlight-color: rgba(26, 26, 26, 0.292969); -webkit-text-size-adjust: none; font-family: '.Helvetica NeueUI'; font-size: 15px; line-height: 19px; white-space: nowrap;">A: start a retail personal genomics company.</span></div>
<div>
<span class="Apple-style-span" style="-webkit-composition-fill-color: rgba(175, 192, 227, 0.230469); -webkit-composition-frame-color: rgba(77, 128, 180, 0.230469); -webkit-tap-highlight-color: rgba(26, 26, 26, 0.292969); -webkit-text-size-adjust: none; font-family: '.Helvetica NeueUI'; font-size: 15px; line-height: 19px; white-space: nowrap;"><br /></span></div>
<div>
<span class="Apple-style-span" style="-webkit-composition-fill-color: rgba(175, 192, 227, 0.230469); -webkit-composition-frame-color: rgba(77, 128, 180, 0.230469); -webkit-tap-highlight-color: rgba(26, 26, 26, 0.292969); -webkit-text-size-adjust: none; font-family: '.Helvetica NeueUI'; font-size: 15px; line-height: 19px; white-space: nowrap;">Saw this (Life Technologies Buys Navigenics in New Gene Diagnostics Strategy</span></div>
<div>
<br /></div>
<div>
<a href="http://pocket.co/sMzhY">http://pocket.co/sMzhY</a>) story today, and while I have no idea of Navigenics really sold for $10M, I would bet a large amount that they sold for less than the $43M invested in Navigenics. The problem, as I see it, wasn't Navigenics' technology, but rather their business strategy to focus on retail genomics. You'd think that investors like Kleiner would know how expensive and difficult attracting consumers is, but their Internet bias drives them towards great tech, not great businesses.</div>
<div>
<br />
<br />
<br /></div>
TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0tag:blogger.com,1999:blog-8770049802106489152.post-62000002022515742292012-06-07T17:43:00.000-04:002012-06-07T17:43:37.643-04:00Positive DNA sequencing news, and a bio-rock star.To balance out the bad news on GNOM, there are two exciting stories of DNA sequencing beginning to generate a revenue stream AND a clinical impact.<br />
<br />
Both Foundation Medicine and <a href="http://www.marketwatch.com/story/verinata-health-announces-successful-introduction-of-its-verifitm-prenatal-test-2012-05-31?siteid=nbkh">Verinata announced</a> the commercial availability of broad diagnostic tests based on DNA sequencing. (<a href="http://www.streetinsider.com/Press+Releases/Foundation+Medicine+Launches+FoundationOne%E2%84%A2/7478316.html">FoundationOne for cancer</a>, Verinata for prenatal health.)<br />
<br />
These tests are exciting because they represent the first commercial adoption of NGS for diagnostic purposes. (Also exciting: neither company is seeking FDA approval for the tests, using the "homebrew" exception to bring them to market, but that's a story for another day.)<br />
<br />
Verinata's news is particularly exciting because the technology requires only a maternal blood sample. This simple blood draw makes possible a number of fetal genetic tests that would otherwise require a risky fetal sample. (Think BIG needle and a chance of long term damage.)<br />
<br />
<br />
Verinata is one of the brain children of Dr. Stephen Quake, a Stanford bioengineering researcher, founder of two public biotechs (Helicos and Fluidigm), and as of this week, <a href="http://phys.org/wire-news/100344631/physicist-and-entrepreneur-dr-stephen-quake-honored-with-500000.html">recipient of the very impressive Lemelson-MIT Prize</a>.<br />
<br />
Biotech lacks "rock stars," which are seemingly so abundant in other industries, particularly computers and the internet, where CEOs like Steve Jobs or Mark Zuckerberg are widely known, and even VCs are get cover stories (like Reid Huffman.) I'd like to see the day where a prolific medicinal chemist is as well-known for his/her efforts as <a href="http://www.cultofmac.com/7402/inside-jonny-ives-design-studio/">Jonny Ive is for his design of Apple products.</a><br />
<br />
(Note: I'm focusing narrowly on biotech people with a commercial impact. Academic scientists like James Watson, Sydney Brenner, and others of course have had HUGE impact, and many have been so honored with Nobel prizes (and the like.) I don't know of any organized honors for commercial success.)<br />
<br />
It'll take some time and a lot more success before the pantheon of biotech rock stars intakes root, but Dr. Quake is a great, if singular example of a biotech rock star.<br />
<br />
<br />
(A few other nominees as biotech rockstars: Jonathan Rothberg, RJ Kirk, Henri Termeer, Alejandro Zaffaroni, Dr. Brian Druker, Arthur Levinson, and Susan Desmond-Hellman. Got any other nominees? Please nominate other names in the comments section.)TimmyGhttp://www.blogger.com/profile/06671327169007709869noreply@blogger.com0